nelfinavir has been researched along with HIV Infections in 544 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 124 (22.79) | 18.2507 |
| 2000's | 377 (69.30) | 29.6817 |
| 2010's | 37 (6.80) | 24.3611 |
| 2020's | 6 (1.10) | 2.80 |
| Authors | Studies |
|---|---|
| Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Colonno, R; Dicker, I; Fan, L; Gali, V; Higley, H; Krystal, M; Lin, PF; Nowicka-Sans, B; Parkin, N; Tenney, D; Terry, B; Wang, C; Zhang, S | 1 |
| Lisovsky, I; Martinez-Cajas, JL; Moisi, D; Oliveira, M; Schader, SM; Wainberg, MA | 1 |
| Fukushima, D; Habashita, H; Hirai, K; Hisaichi, K; Maeda, K; Mitsuya, H; Nakai, H; Nishiyama, T; Nishizawa, R; Sagawa, K; Shibayama, S; Tada, H; Takaoka, Y; Toda, M | 1 |
| Agrawal, N; Chmielewski, J; Hrycyna, CA; Lan, J; Rowe, J; Yu, Q | 1 |
| Bihani, SC; Gupta, GD; Hosur, MV | 1 |
| Abdelnabi, R; Annaert, PP; Augustijns, PF; Cambier, S; Chatterjee, AK; Coelmont, L; Dallmeier, K; De Jonghe, S; Delang, L; Foo, CS; Gouwy, M; Heylen, E; Jochmans, D; Kaptein, SJF; Leyssen, P; Mols, R; Neyts, J; Proost, P; Rocha-Pereira, J; Ter Horst, S; van Laer, C; Vandooren, J; Vangeel, L; Vergote, V; Weynand, B; Zhang, X | 1 |
| Du, F; Feng, XL; Ge, G; Gong, L; Han, JB; Ji, J; Jiang, X; Li, C; Ling, Y; Lu, X; Peng, C; Shen, J; Shi, D; Song, TZ; Tian, RR; Wang, P; Wang, Z; Wu, C; Wu, J; Wu, N; Xu, Y; Xu, Z; Yang, J; Yao, H; Zang, Y; Zhang, J; Zhang, Y; Zheng, M; Zheng, YT; Zhu, M; Zhu, W | 1 |
| Fujii, Y; Fukushige, Y; Hanaoka, H; Hanawa, M; Hori, M; Hosogaya, N; Iwami, S; Izumikawa, K; Kawasaki, Y; Kohno, S; Kurokawa, T; Miyazaki, T; Miyazaki, Y; Morimoto, S; Mukae, H; Takemori, S; Wakita, T; Watashi, K; Yamagoe, S; Yamamoto, H; Yanagihara, K | 1 |
| Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X | 1 |
| Amadori, L; Björkegren, JLM; Crane, HM; Crane, PK; Dudley, JT; Frades, I; Giannarelli, C; Koplev, S; Kovacic, JC; Peter, I; Readhead, B; Talukdar, HA | 1 |
| Aulicino, PC; Mangano, A; Rocco, CA; Rossi, AH; Sen, L | 1 |
| Alobwede, SM; Kongnyuy, EJ; Shey, MS; Wiysonge, CS | 1 |
| Gerlach, SL; Göransson, U; Izadpanah, R; Mondal, D; Roy, U; Yeshak, M | 1 |
| Kolli, M; Kurt-Yilmaz, N; Ozen, A; Schiffer, CA | 1 |
| Anderson, AM; Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Gottlieb, GS; Tchounga, BK; Tegbe, J; Vitoria, M | 1 |
| Bernabeu, E; Chiappetta, DA; Flor, S; Höcht, C; Lucangioli, S; Moretton, MA; Taira, C | 1 |
| Boyko, EJ; Bryson, CL; Ioannou, GN; Weiss, NS | 1 |
| Boucoiran, I; Burchett, S; Frenkel, L; Gantt, S; Huang, ML; Jacobsen, DL; Jerome, KR; Jourdain, G; Leister, E; Ngo-Giang-Huong, N | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Goyal, S; Grover, A; Gupta, A; Jain, R; Jamal, S; Wahi, D | 1 |
| Ande, A; Kumar, A; Kumar, S; Li, J; Li, W; Nookala, AR; Vaidya, NK; Wang, L | 1 |
| Boettiger, DC; Bonnet, F; Bower, M; Fätkenheuer, G; Grulich, A; Kirk, O; Law, M; Lundgren, JD; Monforte, Ad; Phillips, A; Reiss, P; Ryom, L; Sabin, CA | 1 |
| Camacho, RJ; Clotet, B; Cozzi-Lepri, A; Deforche, K; Kjaer, J; Lundgren, JD; Moreau, Y; Phillips, A; Theys, K; Van Laethem, K; Vandamme, AM | 1 |
| Amici, R; Baroncelli, S; Cusato, M; Floridia, M; Galluzzo, CM; Molinari, A; Pinnetti, C; Pirillo, MF; Regazzi, M; Sabbatini, F; Tamburrini, E; Villani, P | 1 |
| Adani, GL; Bresadola, V; Furlanut, M; Londero, A; Pavan, F; Pea, F; Tavio, M; Viale, P | 1 |
| Best, BM; Burchett, SK; Capparelli, EV; Febo, I; Holland, DT; Hu, C; Mirochnick, M; Read, JS; Shearer, WT; Sheeran, EC; Smith, ME; Stek, AM | 1 |
| Krauchenco, S; Martins, NH; Polikarpov, I; Sanches, M | 1 |
| Aste, N; Atzori, L; Ferreli, C; Pau, M; Pilloni, L; Pinna, AL | 1 |
| Bashan, N; Hollander, L; Klein, J; Kovsan, J; Maissel, A; Mazor, L; Meier, B; Osnis, A; Ovadia, S; Rudich, A; Tarnovscki, T | 1 |
| Abecasis, AB; Camacho, RJ; Santos, AF; Soares, MA; Vandamme, AM | 1 |
| Asensi, V; Carton, JA; Collazos, J; Ibarra, S | 1 |
| Afonso, AO; Cunha, SM; Lemey, P; Machado, ES; Nissley, DV; Oliveira, RH; Soares, MA | 1 |
| Bukrinsky, M; Cui, HL; Dart, A; Grant, A; Mukhamedova, N; Rose, H; Sviridov, D; Tchoua, U | 1 |
| Agan, B; Barthel, RV; Crum-Cianflone, NF; Fraser, S; Ganesan, A; Hullsiek, KH; Marconi, V; Roediger, MP; Wegner, S; Weintrob, A | 1 |
| Chichino, G; Donadel, E; Genco, F; Ladisa, N; Malicarne, L; Martini, S; Masala, A; Maserati, R; Meroni, V; Narciso, P; Occhino, C; Perini, P; Ravasi, G; Testa, L; Uglietti, A | 1 |
| Anderson, JR; Argani, CH; Silva, AM; Stohl, HE | 1 |
| Kongnyuy, EJ; Shang, J; Shey, M; Wiysonge, CS | 1 |
| Asensi, V; Cartón, JA; Collazos, J | 3 |
| Aweeka, F; Burchett, SK; Capparelli, E; Fenton, T; Kovacs, A; Nachman, S; Saitoh, A; Sarles, E; Singh, KK; Spector, SA; Wiznia, A | 1 |
| Cheng, I; Kuritzkes, DR; Paredes, R; Tuomala, RE | 2 |
| Barbarino, A; Bruzzese, E; Giannattasio, A; Guarino, A; Lo Vecchio, A; Mango, C | 1 |
| Anceschi, MM; Ascenzi, P; Ivanovic, J; Mattia, E; Narciso, P; Nicastri, E; Notari, S; Pisani, G; Pucillo, LP; Signore, F; Tempestilli, M; Vallone, C | 1 |
| Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J | 1 |
| Asuncion, A; Berry, GJ; Chapman, CH; Dimmick, KW; Filion, EJ; Green, J; Hara, W; Loo, BW; Marko, D; Shen, J; Tran, PT; Wakelee, H | 1 |
| Bhasin, VK; Bhattacharya, A; Mishra, LC; Sharma, M | 1 |
| Alvar, J; Cañavate, C; Dagger, F; Moreno, J; Rangel, A; Saugar, JM; Valdivieso, E | 1 |
| Brinkman, K; Claessen, FA; Mulder, JW; Prins, JM; Regez, RM; Sonder, GJ; van den Hoek, A; Veenstra, J | 1 |
| Beheydt, G; Camacho, RJ; Deforche, K; Lemey, P; Moreau, Y; Rhee, SY; Shafer, RW; Theys, K; van Laethem, K; Van Wijngaerden, E; Vandamme, AM | 1 |
| Earla, R; Jin, M; Kumar, A; Kumar, S; Mitra, AK | 1 |
| Alteri, C; Cella, E; Ciccozzi, M; Ciotti, M; Drašković, N; Fabeni, L; Lai, A; Laušević, D; Lo Presti, A; Marjanovic, A; Mugoša, B; Santoro, MM; Vratnica, Z; Vujošević, D; Zehender, G | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Quesenberry, CP; Ranatunga, DK; Saberi, P; Silverberg, MJ | 1 |
| Bryson, Y; Camarca, M; Mirochnick, M; Mofenson, L; Moye, J; Nielsen-Saines, K; Pilotto, JH; Pinto, J; Rossi, S; Veloso, VG; Watts, DH | 1 |
| Ellis, GM; Frenkel, LM; Hitti, J; Huang, S | 1 |
| Anu, R; Cauda, R; De Donatis, GM; Gillet, JP; Gottesman, MM; Handley, M; Lucia, MB; Wu, CP | 1 |
| Agut, H; Caumes, E; Challine, D; Deback, C; Lascaux, AS; Lévy, Y; Melica, G | 1 |
| Akhtar, H; Boulassel, MR; Bourbeau, M; Burger, DM; Cameron, DW; Chauhan, BM; DelBalso, L; Foster, BC; Lalonde, RG; Seguin, I; Sheehan, NL; Singhal, N; van Heeswijk, RP | 1 |
| Asahchop, EL; Brenner, BG; Doualla-Bell, F; Grossman, Z; Lisovsky, I; Martinez-Cajas, JL; Mendelson, E; Moisi, D; Oliveira, M; Wainberg, MA | 1 |
| Boer, K; Godfried, MH; Nellen, J; Scherpbier, H; van Hoog, S | 1 |
| Bastos, FI; Bethel, J; Bryson, YJ; Camarca, M; Ceriotto, M; Dickover, R; Fonseca, R; Gray, G; Grinsztejn, B; Joao, EC; Kreitchmann, R; Machado, D; Mirochnick, M; Mofenson, LM; Moreira, RI; Morgado, MG; Moye, J; Mussi-Pinhata, MM; Nielsen-Saines, K; Pilotto, JH; Pinto, J; Santos, B; Siberry, G; Theron, G; Veloso, VG; Watts, DH; Xu, J | 1 |
| Akoth, B; Angira, F; Masaba, R; Mills, LA; Minniear, TD; Ndivo, R; Oyaro, B; Peters, PJ; Polle, N; Thomas, TK; Zeh, C | 1 |
| Fätkenheuer, G; Hartmann, P; Jung, N; Lehmann, C; Rubbert, A; Schömig, E; Taubert, D | 1 |
| Branquinha, MH; d'Avila-Levy, CM; Pedroso e Silva, CM; Santos, AL; Santos, LO; Vitório, BS | 1 |
| Breilh, D; Caumont, A; Fleury, HJ; Garrigue, I; Le Camus, C; Montestruc, F; Morlat, P; Pellegrin, I; Pellegrin, JL; Saux, MC | 1 |
| Gazzard, BG; Mandalia, S; Nelson, MR; Pozniak, AL; Walsh, JC | 1 |
| Beijnen, JH; de Koning, LA; Heymans, HS; Hoetelmans, RM; Lange, JM; Scherpbier, HJ; van Heeswijk, RP | 1 |
| Gamarnik, A; Parkin, N; Resch, W; Swanstrom, R; Ziermann, R | 1 |
| Belohradsky, BH; Eberle, J; Funk, M; Gürtler, L; Hoffmann, F; Linde, R; Notheis, G; Petropoulou, T; Wintergerst, U | 1 |
| Bergshoeff, AS; Burger, DM; De Groot, R; Fraaij, PL; Geelen, SP; Hartwig, NG; Hugen, PW; van Rossum, AM; Weemaes, CM; Wolfs, TF | 1 |
| Ait-Khaled, M; Babiker, A; de Rossi, A; Gibb, DM; Kaye, S; Muñoz-Fernandez, M; Pillay, D; Walker, AS | 1 |
| Fridell, JA; Fung, J; Gadomski, M; Jain, AK; Korecka, M; Ragni, M; Shaw, LM; Venkataramanan, R | 1 |
| Biasin, M; Clerici, M; Di Pietro, M; Lo Caputo, S; Maserati, R; Mazzotta, F; Ravasi, G; Seminari, E; Trabattoni, D | 1 |
| Antinori, A; Cingolani, A; De Luca, A; Perna, CF; Van Laethem, K; Vandamme, AM | 1 |
| Aranda, M; Badía, X; Barrufet, P; Cahn, P; Casado, A; Casiró, A; Consiglio, E; Estela, J; Ferrer, E; Gatell, JM; González, A; Llibre, JM; Lozano, L; Luna, E; Lupo, S; Maños, M; Martínez-Lacasa, J; Miró, JM; Ocaña, I; Pedrol, E; Perez, JL; Perez, P; Podzamczer, D | 1 |
| Likanonsakul, S; Moolasart, P | 1 |
| Brundage, RC; Douglas, SD; Fletcher, CV; Flynn, PM; Kline, MW; Spector, SA; Starr, SE; Yong, FH | 1 |
| Grub, S; Jorga, K; Kline, MW; Schwarzwald, HL | 1 |
| Martínez Losada, EJ; Pedrol Clotet, E; Rodellar Oncins, MT; Soler Sendra, A | 1 |
| Deutsch, P; Havlir, D; Kerr, B; Lewis, RH; Peng, Y; Riddler, SA; Saah, A; Squires, KE; Wynne, LH; Yeh, K; Zhong, L | 1 |
| Ceccaldi, PF; Deleuze, J; Dimet, J; Dupin, N; Escande, JP; Gorin, I; Morini, JP; Pons, G; Rey, E; Tréluyer, JM | 1 |
| Abrams, L; Badaro, R; Cross, A; Gathe, J; Grimwood, A; Klesczewski, K; McLaren, C | 1 |
| Justesen, US; Pedersen, C | 1 |
| Piliero, P; Sanne, I; Schnittman, S; Squires, K; Thiry, A | 1 |
| Gerstoft, J; Katzenstein, TL; Nielsen, HL; Røge, BT | 1 |
| Black, FT; Jensen-Fangel, S; Justesen, US; Obel, N; Pedersen, C | 1 |
| Compagnucci, A; Faye, A; Giaquinto, C; Gibb, DM; Harper, L; Jacqz-Aigrain, E; Litalien, C | 1 |
| Compagnucci, A; Giacomet, V; Gibb, DM; Goodall, RL; Lyall, H; McGee, L | 1 |
| de Groot, R; Gaakeer, MI; Geelen, SP; Hartwig, NG; Lamberts, SW; Van Rossum, AM; Verweel, S; Wolfs, TF | 1 |
| Aarnoutse, RE; Burger, DM; Hoetelmans, RM; Hugen, PW; Jambroes, M; Lange, JM; Nieuwkerk, PT; Schneider, MM; Schreij, G; van der Ende, ME | 1 |
| de Mendoza, C; Gonzàlez de Requena, D; Jiménez-Nàcher, I; Núñez, M; Soriano, V | 1 |
| Arnaud, A; Mauboussin, JM; Peyrière, H; Rouanet, I; Vincent, D | 1 |
| Diaz, RS; Filho, AC; Medeiros, R | 1 |
| Antoniou, T; Park-Wyllie, LY | 1 |
| Arnedo, M; Barberá, MJ; Ferrer, E; Fumero, E; Gatell, JM; Gudiol, F; McKenna, P; Pérez, JL; Podzamczer, D; Pumarola, T; Rinehart, A | 1 |
| Bratt, G; Ståhle, L | 1 |
| Bergshoeff, AS; Burger, DM; Geelen, SP; Wolfs, TF | 1 |
| Bakshi, KK; Chen, J; Condra, JH; Danovich, RM; DiNubile, MJ; Graham, DJ; Haas, DW; Holder, DJ; Rhodes, RR; Saah, AJ; Shivaprakash, M | 1 |
| Aziz, D; Bean, P; Graziano, FM; Neudeck, BL; Urban, AW | 1 |
| Carr, A; Cooper, DA; Cunningham, PH; Duncombe, C; Grey, PA; Hecht, FM; Kahn, JO; Kaufmann, GR; Petersen, A; Quan, DC; Smith, DE; Zaunders, JJ | 1 |
| Calza, L; Manfredi, R | 2 |
| Feinberg, J; Goodrich, J; Greenberg, RN; Pilson, RS; Siemon-Hryczyk, P | 1 |
| Calza, L; Chiodo, F; Manfredi, R | 1 |
| Aquilina, C; Boué, F; Brun-Vezinet, F; Descamps, D; Goetschel, A; Lafeuillade, A; Livrozet, JM; Mamet, JP; Matheron, S; Thiaux, C; Troisvallets, D | 1 |
| Burger, DM; Droste, JA; Verweij-Van Wissen, CP | 1 |
| Bassetti, D; Bernardi, S; Castelli-Gattinara, G; Cruciani, M; De Pascalis, CR; Gatti, G; Miletich, F; Papa, L; Pontali, E | 1 |
| Bon, I; Borderi, M; Calza, L; Chiodo, F; Farneti, B; Monari, P; Re, MC; Tampellini, L | 1 |
| Bartlett, JG; Celentano, DD; Lai, H; Lai, S; Lima, JA; Margolick, J; Ren, S; Vlahov, D | 1 |
| Aarnoutse, R; Brinkman, K; Burger, D; Gyssens, I; Hugen, P; Kroon, F; Lange, J; Prins, J; Reiss, P; Richter, C; Schneider, M; Schreij, G | 1 |
| Aweeka, FT; Beckerman, KP; Hayashi, S; Homma, M; Kosel, BW | 1 |
| Genka, I; Kikuchi, Y; Kimura, S; Matsuoka-Aizawa, S; Oka, S; Tachikawa, N; Teruya, K; Tsuchiya, K; Yasuoka, A | 1 |
| DeGruttola, V; Foulkes, AS | 1 |
| Albert, J; Blaxhult, A; Brandin, E; Broström, C; Gisslen, M; Gyllensten, K; Hagberg, L; Lindborg, L; Tuvesson, B | 1 |
| Bergshoeff, AS; Burger, DM; de Groot, R; Fraaij, PL; Geelen, SP; van Rossum, AM; Wolfs, TF | 1 |
| Collier, AC; Dehlinger, M; Demeter, LM; Erice, A; Eron, JJ; Eshleman, SH; Feinberg, JE; Fischl, MA; Giuliano, M; Hammer, SM; Morse, GD; Ribaudo, HJ; Saag, MS; Vella, S | 1 |
| Aberg, JA; Abrams, DI; Aweeka, FT; Bacchetti, P; Benowitz, NL; Bredt, BM; Deeks, SG; Elbeik, TA; Hilton, JF; Kosel, B; Leiser, RJ; McCune, JM; Mitchell, TF; Mulligan, K; Schambelan, M; Shade, SB | 1 |
| Adonis-Koffy, L; Fassinou, P; N'dja, BB; Timité-Konan, AM | 1 |
| Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, L; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Adjé-Touré, CA; Borget, MY; Bouchez, JM; Cheingsong, R; Chorba, T; Eholié, S; Ekpini, RE; Garcìa-Lerma, JG; Heneine, W; Maurice, C; Nkengasong, JN; Nolan, M; Otten, RA; Sassan-Morokro, M | 1 |
| Brun-Vézinet, F; Chêne, G; Dary, M; Descamps, D; Droz, C; Ferré, V; Masquelier, B; Perronne, C; Raffi, F; Spire, B | 1 |
| Barbera, MJ; Ferrer, E; Fisac, C; Fumero, E; Podzamczer, D; Vilarasau, C; Virgili, N | 1 |
| Aliaga, L; Barrera, A; Colmenero, MA; de Alarcón, A; de la Torre, J; Gutiérrez-Ravé, V; Hernández-Quero, J; Lozano, F; Marín, J; Márquez, M; Milla, M; Pérez-Guzmán, E; Pujol, E; Suárez, I; Torres-Tortosa, M; Valdayo, MJ; Vergara, A; Viciana, P | 1 |
| Bouvet, E; Chêne, G; Cottalorda, J; de Boever, CM; Journot, V; Le Moing, V; Leport, C; Peytavin, G; Préau, M; Raffi, F | 1 |
| Becker, MI; D'Aquila, RT; De Gruttola, V; Delapenha, R; Dubé, MP; Fischl, MA; Gedeon, L; Hirsch, MS; Merigan, TC; Murphy, RL; Pettinelli, C; Pollard, RB; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; van der Horst, C; Vella, S | 1 |
| D'Aquila, RT; De Gruttola, V; Gripshover, BM; Haubrich, R; Hirsch, MS; Johnson, VA; Kaul, P; Martinez, AI; McCarty, SD; Merigan, TC; Morse, GD; Nokta, MA; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; Swingle, M; Vella, S | 1 |
| Cahn, P; Giordano, M; Kelleher, T; Murphy, RL; Percival, L; Phanuphak, P; Sanne, I | 1 |
| Bauer, E; Bernstein, B; Brun, S; Cernohous, P; Gu, K; Hsu, A; Kempf, DJ; King, MS; Moseley, J; Sun, E | 1 |
| Boghossian, J; Gray, GE; Millard, JM; Nadler, JP; Quinones, AR; Rodriguez-French, A; Sepulveda, GE; Wannamaker, PG | 1 |
| Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, LR; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Angel, JB; Badley, AD; Cooper, CL; Hawley, N; Lum, JJ; Mbisa, G; Parato, K; Phenix, B | 1 |
| Collier, A; DiCenzo, R; DiFrancecso, R; Feinberg, J; Fischl, MA; Forrest, A; Morse, GD; Ribaudo, H | 1 |
| Bini, T; Bongiovanni, M; Chiesa, E; Monforte, Ad | 1 |
| Clotet, B | 1 |
| Acosta, EP; Brundage, RC; Fletcher, CV; Gulick, RM; Haubrich, R; Jiang, H; Katzenstein, D | 1 |
| Cardellach, F; Casademont, J; García-Viejo, MA; Gatell, JM; López, S; Martínez, E; Milinkovic, A; Miró, O; Nunes, V; Pedrol, E; Rodríguez-Santiago, B; Soler, A | 1 |
| Back, DJ; Cornforth, D; Cuthbertson, Z; Daniels, E; Ford, J; Hoggard, PG; Hsyu, P; Johnson, M; Khoo, SH; Meaden, ER; Williams, I | 1 |
| Back, D; Barry, M; Clarke, S; Hennessy, M; Hoggard, P; Kelleher, D; Mulcahy, F; Spiers, JP | 1 |
| Deray, G; Hulot, JS; Izzedine, H; Launay-Vacher, V | 1 |
| Das, S; Schray, KJ; Sipos, T; Stewart, RP; Wignot, TM | 1 |
| Alper, SL; Andrade, A; Flexner, C; Jiang, L; Lencer, WI; Lin, PW; Rameh, L; Rufo, PA | 1 |
| Aboulker, JP; Babiker, A; Chaix, ML; Compagnucci, A; Darbyshire, J; Debré, M; Faye, A; Giaquinto, C; Gibb, DM; Harper, L; Saïdi, Y; Walker, AS | 1 |
| Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B | 1 |
| Doyle, ME; Ellis, KJ; Hardin, DS; Rice, J | 1 |
| Averbuch, D; Engelhard, D; Grossman, Z; Istomin, V; Lorber, M; Maayan, S; Mendelson, E; Parkin, NT; Paxinos, EE; Petropoulos, CJ; Ram, D; Schapiro, JM; Shaked, Y | 1 |
| Cahn, P; Giordano, M; Kelleher, T; Mancini, M; Murphy, R; Pantaleo, G; Phanuphak, P; Pokrovskiy, V; Rozenbaum, W; Sension, M; Wood, R | 1 |
| Conner, SD; Covington, DL; Daniels, EM; Doi, PA; Swinson, J | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ | 1 |
| Bernstein, BM; Brun, SC; Cernohous, P; Feinberg, J; King, MS; Montaner, JS; Sanne, I; Sherer, R; Sun, E; Walmsley, SL | 1 |
| DeSilva, KE; Guest, JL; Rimland, D; Ruffin, C; Tschampa, JM | 1 |
| Albert, I; Bénoliel, S; Brun-Vézinet, F; Duval, X; Ecobichon, JL; Leport, C; Mentré, F; Peytavin, G; Vildé, JL | 1 |
| Bellos, NC; DeJesus, E; Garris, C; Gathe, JC; Gladysz, A; Ive, P; Schürmann, D; Wood, R; Yeo, J | 1 |
| Chiesi, A; Fisher, M; Horban, A; Kirk, O; Ledergerber, B; Lundgren, JD; Machala, L; Mulchany, F; Phillips, AN; Reiss, P | 1 |
| Abreu, CM; Aguiar, RS; Brindeiro, RM; Gonzalez, LM; Pereira, HS; Soares, MA; Tanuri, A | 1 |
| Bernard, E; Del Giudice, P; Dellamonica, P; Marq, L; Perrin, C; Vandenbos, F | 1 |
| Bergshoeff, AS; Burger, DM; De Groot, R; Gibb, D; Hoetelmans, RM; Tréluyer, JM; Walker, S | 1 |
| Chappuy, H; Dimet, J; Firtion, G; Fouché, M; Mandelbrot, L; Pons, G; Rey, E; Tréluyer, JM | 1 |
| Bergshoeff, AS; Boer, K; Burger, DM; Godfried, MH; Lange, JM; Nellen, JF; Prins, JM; Schillevoort, I; Wit, FW | 1 |
| Demeter, LM; Erice, A; Eshleman, SH; Fischl, MA; Hammer, SM; Hellmann, NS; Ribaudo, HJ | 1 |
| Burger, DM; Grintjes, KJ; Koopmans, PP; Lotgering, FK | 1 |
| Afonso, AO; Costa, AJ; Cunha, SM; Lambert, JS; Machado, ES; Oliveira, RH; Sill, AM; Soares, MA; Tanuri, A | 1 |
| Boer, K; Dieleman, JP; Godfried, MH; Tempelman, C; Timmermans, S; van der Ende, ME | 1 |
| Chaisson, RE; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL | 1 |
| Gerber, JG; Wyles, DL | 1 |
| Goto, M; Iwamoto, A; Kitamura, Y; Kotaki, H; Nakamura, T; Odawara, T; Sugiura, W; Taguchi-Nakamura, H; Yamada, H; Zhu, D | 1 |
| Bressolle, F; Compagnucci, A; Faye, A; Giaquinto, C; Gibbs, D; Gomeni, R; Jacqz-Aigrain, E; Payen, S | 1 |
| Briganti, E; Castelli, P; Cusato, M; Delle Foglie, P; Fabris, P; Gatti, F; Maserati, R; Mori, F; Nardini, G; Regazzi, M; Roda, R; Sacchelli, L; Testa, L; Villani, P; Zucchi, P | 1 |
| Coupal, L; Gilmore, N; Grover, SA; Mukherjee, J | 1 |
| Bassetti, D; Bassetti, M; Cinelli, R; Cruciani, M; Di Gennaro, G; Gatti, G; Tirelli, U; Vaccher, E | 1 |
| Brundage, R; Fenton, T; Fletcher, CV; Powell, CA; Saitoh, A; Singh, KK; Spector, SA; Starr, S | 1 |
| Bedoni, AJ; Figueiredo, RM; Garcia, MT; Moretti, ML; Papaiordanou, PM; Resende, MR | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 1 |
| Arasteh, K; Artigas, JG; Clotet, B; Danise, A; Foreman, R; Gonzalez-Garcia, J; Horban, A; Johnson, M; Landman, R; Nieto-Cisneros, L; Proll, S; Smith, P; Snowden, W | 1 |
| Alvaro-Meca, A; de José, MI; Gurbindo, MD; Martin-Fontelos, P; Muñoz-Fernández, MA; Ramos, JT; Resino, S | 1 |
| Brown, AJ; Clotet, B; Frost, SD; Martinez-Picado, J; Parkin, NT; Petropoulos, CJ; Ruiz, L; Wrin, T | 1 |
| Becker, M; Breske, A; Esser, S; Hill, A; Koerber, A; Kopperman, M; Kruse, G; Kurowski, M; Möcklinghoff, C; Ross, B; Stocker, H; Wiehler, H | 1 |
| Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME | 1 |
| Amin, J; Carr, A; Cooper, DA; McAllister, J; Winston, A | 1 |
| Bruno, R; Filice, G; Maiocchi, L; Sacchi, P; Zocchetti, C | 1 |
| Brun, SC; Kempf, DJ; King, MS | 1 |
| Abduch, R; Duarte, G; El Beitune, P; Figueiró-Filho, EA; Machado, AA; Quintana, SM | 1 |
| Bergroth, T; Knut, L; Lindkvist, A; Sönnerborg, A; Svedhem, V | 1 |
| Barroso, PF; Boechat, LJ; Melo, MF; Schechter, M; Vettore, MV | 1 |
| Burger, DM; Droste, JA; Hekster, YA; Koopmans, PP | 1 |
| Fischl, MA; Forrest, A; Hirsch, MS; Merigan, TC; Morse, GD; Park, JG; Robbins, GK; Shafer, RW; Smith, PF; Wu, H; Yu, S | 1 |
| Andersen, AB; Black, FT; Gerstoft, J; Hansen, IM; Justesen, US; Klitgaard, NA; Mathiesen, LR; Pedersen, C | 1 |
| Brun, S; Cernohous, P; Da Silva, B; Omachi, JH; Rouster, SD; Sherman, KE; Shire, NJ | 1 |
| Briganti, E; Castelli, P; Cusato, M; De Silvestri, A; Foglie, PD; Gatti, F; Maserati, R; Mori, F; Nardini, G; Regazzi, MB; Roda, R; Sacchelli, L; Testa, L; Tinelli, C; Villani, P; Zucchi, P | 1 |
| Diquet, B; Goujard, C; Legrand, M; Mentré, F; Panhard, X; Taburet, AM | 2 |
| Aldámiz-Echevarría, L; Elorz, J; Pocheville, I; Prieto, JA; Rodríguez-Soriano, J; Sanjurjo, P | 1 |
| Acosta, EP; Aldrovandi, G; Chen, J; Damle, B; Hodge, J; Hughes, MD; King, JR; Nachman, S; Wiznia, A; Yogev, R | 1 |
| Cvetković, RS; Frampton, JE; McCormack, PL; Perry, CM; Siddiqui, MA | 1 |
| Benhaim, S; Drogoul-Vey, MP; Frixon-Marin, V; Gastaut, JA; Marimoutou, C; Poggi, P; Poizot-Martin, I; Vion-Dury, F | 1 |
| Dubé, MP; Grinspoon, SK; Meyer, WA; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Shafer, RW; Snyder, SW; Tebas, P; Wininger, DA; Zackin, RA | 1 |
| Clifford, DB; D'Aquila, RT; De Gruttola, V; Donahue, JP; George, AL; Haas, DW; Hirsch, MS; Kim, RB; Labbe, L; Merigan, TC; Morse, GD; Pollard, RB; Robbins, GK; Shafer, RW; Smeaton, LM; Wilkinson, GR | 1 |
| Aleixo, A; Greco, D; Tupinambás, U | 1 |
| Boix, V; Garcia-Henarejos, JA; Gimeno, A; Llopis, C; Martínez-Madrid, O; Merino, E; Portilla, J; Sánchez-Paya, J | 1 |
| Bonnet, B; Diquet, B; Duval, X; Goujard, C; Katlama, C; Legrand, M; Leport, C; Mentré, F; Panhard, X; Peytavin, G; Salmon-Céron, D; Taburet, AM; Vincent, I | 1 |
| Averitt, D; Kumar, PN; Pakes, GE; Pappa, KA; Rodriguez-French, A; Shaefer, MS; Tashima, KT; Thompson, MA; Wannamaker, PG; Williams, VC | 1 |
| Cardellach, F; Casademont, J; Garrabou, G; Gatell, JM; Giralt, M; López, S; Martínez, E; Miró, O; Pedrol, E; Rodríguez de la Concepción, M; Villarroya, F; Villarroya, J | 1 |
| Amed, AM; Kulay, L; Mathias, CF; Mathias, CV; Oliveira-Filho, RM; Simões, MJ; Simões, RS | 1 |
| Bekker, V; Jurriaans, S; Kuijpers, TW; Lange, JM; Scherpbier, HJ; van Leth, F | 1 |
| Calvez, V; Katlama, C; Malet, I; Marcelin, AG; Peytavin, G; Roquebert, B; Simon, A; Tubiana, R; Valantin, MA; Wirden, M | 1 |
| Fuchs, D; Gisslén, M; Hagberg, L; Nillroth, U; Ståhle, L; Svensson, JO; Yilmaz, A | 1 |
| Bacheler, L; Corral, A; de Mendoza, C; Pattery, T; Soriano, V; Valer, L | 1 |
| Karlström, O; Perrin, L; Sönnerborg, A; Ståhle, L; Tegude, H | 1 |
| Brown, LS; Chu, M; Kritz, S; Madray, C | 1 |
| Arizcorreta-Yarza, A; Becker, MI; Caballero-Granado, FJ; Girón-González, JA; Gómez-Mateos, J; González-Serrano, M; Jiménez-Mejías, ME; Macías, J; Merino, D; Mira, JA; Pineda, JA; Terrón, A; Torre-Cisneros, J | 1 |
| Avalos, A; Brenner, B; Doualla-Bell, F; Essex, M; Gaolathe, T; Gaseitsiwe, S; Mine, M; Moffat, H; Moisi, D; Ndwapi, N; Novitsky, VA; Oliveira, M; Thior, I; Wainberg, MA | 1 |
| Beijnen, JH; Crommentuyn, KM; Huitema, AD; Kuijpers, TW; Mathôt, RA; Scherpbier, HJ | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Garazzino, S; Tettoni, M | 1 |
| de José, MI; Larrú, B; Léon, JA; Maria Bellón, J; Mellado, MJ; Muñoz-Fernández, MA; Navarro, M; Ramos, JT; Resino, R; Resino, S | 1 |
| Aymard, G; Bergmann, JF; Mahé, I; Mouly, S; Rizzo-Padoin, N; Salvat, C; Simoneau, G; Verstuyft, C | 1 |
| Olmo, M; Podzamczer, D | 1 |
| Bond, SJ; Sarah Walker, A; White, IR | 1 |
| Cavaliere, AF; Cusato, M; degli Antoni, A; Floridia, M; Guaraldi, G; Molinari, A; Pirillo, MF; Regazzi, M; Tamburrini, E; Vanzini, C; Villani, P | 1 |
| Harris, M; Hogg, RS; Montaner, JS; Moore, DM; Wood, E; Yip, B | 1 |
| Abecasis, AB; Bacheler, LT; Camacho, RJ; Carvalho, AP; Deforche, K; Gomes, P; McKenna, P; Vandamme, AM | 1 |
| Biollaz, J; Buclin, T; Colombo, S; Décosterd, LA; Eap, CB; Furrer, H; Lee, BL; Telenti, A | 1 |
| Casado, JL; Collazos, J; Knobel, H | 1 |
| Anaky, MF; Blanche, S; Fassinou, P; Inwoley, A; Kouakoussui, A; Msellati, P; Rouet, F; Rouzioux, C | 1 |
| Ariyoshi, K; Bouzas, MB; Brigido, LF; Cahn, P; Camacho, R; Cane, P; Carvalho, AP; Clarke, J; Deforche, K; Grossman, Z; Harrigan, PR; Holguin, A; Kantor, R; Katzenstein, DA; Moreau, Y; Morris, L; Phanuphak, P; Pillay, D; Rodrigues, R; Rudich, H; Shafer, RW; Shapiro, JM; Silander, T; Sirivichayakul, S; Snoeck, J; Soares, MA; Soriano, V; Sugiura, W; Tanuri, A; Van Laethem, K; Vandamme, AM; Weber, J; Wynhoven, B | 1 |
| Atzori, C; Cargnel, A; Maruzzi, M; Mazza, F; Regazzi, M; Tronconi, E; Valerio, A; Villani, P | 1 |
| Angeletti, C; Boumis, E; Chinello, P; Lisena, FP; Papetti, F; Petrosillo, N | 1 |
| Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Park, JG; Stek, A; Watts, DH; Yu, S | 1 |
| Fessel, WJ; Horberg, M; Hurley, L; Mitsuya, Y; Rhee, SY; Schiffer, CA; Shafer, RW; Winters, MA; Zolopa, AR | 1 |
| Arastéh, K; Becker, M; Berger, M; Breske, A; Herzmann, C; Hill, A; Kruse, G; Kurowski, M; Schulbin, H; Steinmüller, J; Stocker, H | 1 |
| Chew, N; Cotter, E; Doran, PP; Malizia, AP; Powderly, WG | 1 |
| Ceballos, VC; Costa, RV; Domínguez, MV; Florencio, VD; Lara, TE | 1 |
| Badley, AD; Bennett, SA; Vlahakis, SR; Whitehead, SN | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Asboe, D; Babiker, AG; Darbyshire, JH; Goodall, RL; Hooker, MH; Williams, IG | 1 |
| Becker, MI; Benator, DA; Burman, WJ; Engle, M; Hsyu, PH; Jones, BE; Khan, AE; Peloquin, CA; Sandman, L; Silva-Trigo, C; Vernon, AA; Weiner, MH; Zhao, ZA | 1 |
| Dubé, MP; Grinspoon, SK; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Bavoux, F; Benhayoun, M; Brasme, JF; Dauger, S; Faye, A; Lachassinne, E; Mille, F; Teissier, N | 1 |
| Alvero, CG; Brundage, RC; Fenton, T; Fletcher, CV; Mofenson, LM; Powell, C; Spector, SA | 1 |
| Back, DJ; Cane, P; Chandler, B; Detsika, MG; Khoo, SH; Owen, A; Winstanley, C | 1 |
| Campbell, O; de Morais, EN; Duarte, G; El-Beitune, P; Mauad-Filho, F; Quintana, SM; Rodrigues, LC; Spara-Gadelha, P | 1 |
| Amorim, AP; Campos, CP; Custódio, FL; Ferrão, SB; Fonseca, BA; Gaspar, GG; Golin, NA; Marangoni, AT; Melo, Ld; Morejón, KM; Ponzi, CC; Santana, RC; Vanni, T | 1 |
| Campbell, O; Duarte, G; El Beitune, P; Quintana, SM; Rodrigues, LC | 1 |
| Chrysos, G; Kokkoris, S; Kontochristopoulos, G; Mikros, S; Pastelli, A | 1 |
| Bastiani, E; Donadel, E; Genco, F; Maserati, R; Meroni, V; Rinaldi, S; Uglietti, A | 1 |
| Alonso-Socas, Mdel M; Delgado, R; García-Bujalance, S; Garriga, C; Menéndez-Arias, L; Nájera, R; Pérez-Elías, MJ; Pumarola, T; Ruiz, L | 1 |
| Chappuy, H; Firtion, G; Hirt, D; Jullien, V; Mandelbrot, L; Pons, G; Rey, E; Treluyer, JM; Urien, S | 1 |
| Alvero, C; Fenton, T; Fletcher, CV; Saitoh, A; Spector, SA | 1 |
| Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D | 1 |
| Auleley, S; Duval, X; Hirt, D; Mentré, F; Rey, E; Salmon, D; Tran, A; Tréluyer, JM | 1 |
| Baker, R; Brooks, JT; Hoffman, M; Moorman, A; Novak, R; Uy, J | 1 |
| Calmy, A; Carey, DL; Carr, A; Cooper, DA; Emery, S; Law, MG; Samaras, K; Wand, H | 1 |
| Aguiar, RA; Aleixo, A; Cleto, S; Kakehasi, FM; Lin, E; Melo, VH; Pinto, JA; Tupinambás, U | 1 |
| Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Muderspach, L; Park, JG; Stek, A; Watts, DH; Yu, S | 1 |
| Burri, M; Nadal, D; Rode, R; Rudin, C; Shen, Y | 1 |
| Collins, M; Detmer, J; Fultz, T; Hamren, S; Kern, D; Peterkin, JJ; Sheridan, P; Todd, J; Urdea, M; White, R; Yeghiazarian, T | 1 |
| Deeks, SG; Holodniy, M; Kahn, JO; Smith, M | 1 |
| Fox, JL | 1 |
| Cao, Y; Essunger, P; Ho, DD; Hurley, A; Markowitz, M; Perelson, AS; Saksela, K; Vesanen, M | 1 |
| Benfield, P; Perry, CM | 1 |
| Ahle, D; Bushnell, S; Chang, C; Collins, ML; Detmer, J; Fine, E; Ho, DD; Horn, T; Irvine, B; Kolberg, J; Shen, LP; Tyner, D; Urdea, MS; Zayati, C | 1 |
| Bloom, LA; Boritzki, TJ; Patick, AK | 1 |
| Ferrando, S; Rabkin, JG | 1 |
| Back, DJ; Barry, MG; Halifax, KL; Merry, C; Mulcahy, F | 1 |
| Max, B; Mourikes, N | 1 |
| Delwart, EL; Markowitz, M; Neumann, A; Pan, H | 1 |
| Grodesky, MJ; Klaus, BD | 1 |
| Paterson, DL; Singh, N | 1 |
| Chapman, S; Clendeninn, N; Conant, M; Duran, M; Hendricks, A; Ho, DD; Hoskins, W; Hurley, A; Markowitz, M; Patick, A; Peterkin, J; Schluger, R; Yuen, GJ | 1 |
| Burton, S; Carr, A; Chisholm, DJ; Cooper, DA; Freund, J; Law, M; Samaras, K | 1 |
| Faulds, D; Jarvis, B | 1 |
| Back, DJ; Barry, MG; Breckenridge, AM; Halifax, KL; Merry, C; Mulcahy, F; Ryan, M; Tjia, JF | 1 |
| Jackson, RC | 1 |
| Beijnen, JH; de Wolf, F; Frissen, PH; Hoetelmans, RM; Jurriaans, S; Lange, JM; Mulder, JW; Reijers, MH; Roos, M; Schuitemaker, H; ten Kate, RW; Weigel, HM; Weverling, GJ; Wit, FW | 1 |
| Chapman, S; Clendeninn, N; Higgs, C; Monaghan, J; Moyle, GJ; Nelson, MR; Prince, W; Youle, M | 1 |
| Cammack, N; Chirn, GW; Craig, C; Dissanayeke, S; Duncan, IB; Gilbert, S; Moffatt, A; Race, E; Rose, J; Sheldon, J; Whittaker, L | 1 |
| Saag, MS; Schooley, RT | 1 |
| Bousquet, J; Delmas, C; Demoly, P; Dohin, E; Fabre, J; Faucherre, V; Godard, P; Messaad, D; Reynes, J; Trylesinski, A | 1 |
| Chronister, CL; Gurwood, AS | 1 |
| Brew, BJ; Markus, R | 1 |
| Baril, L | 1 |
| Lien, EJ; Ren, S | 1 |
| Holtzer, CD; Varav, H | 1 |
| Bruisten, SM; de Wolf, F; Frissen, PH; Jurriaans, S; Lange, JM; Mulder, JW; Reijers, MH; Schuitemaker, H; ten Kate, RW; van Leeuwen, R; Weigel, HM; Weverling, GJ; Wit, FW | 1 |
| Diehl, V; Fätkenheuer, G; Hoetelmans, R; Reiser, M; Salzberger, B; Stiepel, A | 1 |
| Kuper, JJ; Malaty, LI | 1 |
| Coulaud, JP | 1 |
| Nahata, MC; Pai, VB | 1 |
| Erice, A; Henry, K; Kane, EM; Klebert, MK; Patick, AK; Powderly, WG; Simpson, JH; Tebas, P | 1 |
| Ceballos, J; Iglesias, M; Ostrosky-Zeichner, L; Ponce-de-Leon, S | 1 |
| Carver, PL; Cinti, SK; Kaul, DR; Kazanjian, PH | 1 |
| Bubl, R; Di Gallo, A; Engelcke, G; Rinaldi, D; Rohrer, T; Rudin, C | 1 |
| Becker, M; Chesney, M; Deeks, SG; Grant, RM; Hellmann, NS; Parkin, NT; Petropoulos, CJ; Symonds, W; Volberding, PA | 1 |
| Aoki, M; Honda, M; Oka, S; Yasuoka, A | 1 |
| Lo Caputo, S; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P | 1 |
| Burger, DM; Hekster, YA; Hugen, PW; Koopmans, PP; Verweij-van Wissen, CP; Wuis, EW | 1 |
| Brendel, V; Craig, C; Hsu, P; Patick, AK; Shafer, RW | 1 |
| Angel, JB; Ashby, D; Badley, AD; Cameron, DW; Kravcik, S; Kumar, A; Lynch, DH; Parato, K; Phenix, BN; Tschopp, J | 1 |
| Barnett, SH; Gallant, JE; Hall, CS; Moore, RD; Raines, CP | 1 |
| Altfeld, M; Fätkenheuer, G; Kaiser, R; Kupfer, B; Rockstroh, JK; Salzberger, B; Schneweis, KE; Spengler, U | 1 |
| Clough, LA; D'Agata, E; Haas, DW; Raffanti, S | 1 |
| Albengres, E; Cheminot, N; Escaut, L; Liotier, JY; Vittecoq, D | 1 |
| Benhamou, Y; Bernard, B; Bricaire, F; Di Martino, V; Ezenfis, J; Opolon, P; Poynard, T | 1 |
| Cheseaux, JJ; Darioli, R; Glauser, MP; Halfon, P; Marcovina, SM; Mooser, V; Nicod, P; Périard, D; Reymond, MJ; Sudre, P; Telenti, A | 1 |
| Boczany, B; Bryson, Y; Dankner, W; Gersten, M; Hendricks, A; Jung, D; Kerr, B; Krogstad, P; Luzuriaga, K; Nielsen, K; Rosenberg, M; Spector, SA; Wiznia, A | 1 |
| Landovitz, RJ; Sax, PE | 1 |
| Chavan, SJ; Gersten, M; Kaplan, M; Pahwa, SG; Tamma, SL | 1 |
| Heald, AE; Heffron, S; Schiffman, SS; Zervakis, J | 1 |
| Ahrens, P; Funk, MB; Hoffmann, F; Kornhuber, B; Kreuz, W; Linde, R; Notheis, G; Schuster, T; Wintergerst, U | 1 |
| Deray, G; Diquet, B; Izzedine, H; Jouan, M; Launay-Vacher, V; Theou, N | 1 |
| Angel, JB; Badley, AD; Cameron, DW; Garber, GE; Kravcik, S; Victor, G | 1 |
| Powderly, WG; Tebas, P | 2 |
| Brooks, D; DiMassimo, E; Dusek, A; Eron, JJ; Gleavy, J; Hopkins, S; Ngo, L; Pilcher, CD; Sista, P; Venetta, T | 1 |
| Abumi, H; Ajisawa, A; Fukutake, K; Gouchi, K; Hanabusa, H; Higasa, S; Ishikawa, M; Iwamoto, A; Kakishita, E; Kashiwagi, S; Koike, M; Matsuda, M; Mimaya, J; Miura, T; Nagai, Y; Oishi, T; Okano, A; Shirahata, A; Sugiura, W; Takamatsu, J; Takata, N; Taki, M; Yamada, K | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Castelli, F; Maserati, R; Regazzi, MB; Seminari, E; Torti, C; Viale, P; Villani, P | 1 |
| Elmadfa, I; Jilma, B; Parschalk, B; Pernerstorfer-Schoen, H; Schindl, A; Schindler, K; Thoeny-Lampert, S; Tschachler, E; Wunderer, K | 1 |
| Becker, M; Brundage, RC; Dankner, WM; Fenton, T; Fiske, W; Fletcher, CV; Flynn, PM; Gersten, M; Graham, B; Kornhauser, DM; Lischner, HW; Manion, D; McNamara, J; Mofenson, LM; Purdue, L; Ruiz, N; Siminski, S; Spector, SA; Starr, SE; Vincent, C; Yong, FH | 1 |
| Clumeck, N | 1 |
| Walters, S | 1 |
| George, SL; Knudson, R; Stapleton, JT; Swindells, S | 1 |
| Henry, K; Staudinger, R | 1 |
| Belohradsky, BH; Eberle, J; Gürtler, L; Hoffmann, F; Notheis, G; Wintergerst, U | 1 |
| Butcher, D; Duong, P; Greene, J; Markson, L | 1 |
| Chiodo, F; Manfredi, R | 2 |
| Farber, S; McCance-Katz, EF; O'Connor, A; Selwyn, PA | 1 |
| Fiocchi, C; Gambarana, E; LoCaputo, F; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P | 1 |
| Arnedo, A; Gómez, CJ; Roca, B | 2 |
| Bernasconi, E; Carota, A; Magenta, L; Moccetti, T; Piffaretti, JC | 1 |
| Armbruster, C; El Menyawi, I; Meisl, FT; Neumann, I; Vorbach, H | 1 |
| Fortuny, C; González-Enseñat, A; Medina, MM; Vicente, MA | 1 |
| Beguinot, I; Bernard, P; Derancourt, C; Drobacheff, C; Verraes, S | 1 |
| Klinker, H; Langmann, P; Richter, E; Schlör, C; Väth, T; Weissbrich, B; Zilly, M | 1 |
| Skowron, G | 1 |
| Anderson, RD | 1 |
| Bart, PA; Chapuis, A; De Boer, RJ; Fox, CH; Halkic, N; Hoover, S; Lange, JM; Lazzarin, A; Miller, V; Notermans, DW; Pantaleo, G; Perrin, L; Rizzardi, GP; Staszewski, S; Tambussi, G | 1 |
| Clumeck, N; DelFraissy, JF; DeLora, P; Duff, F; Johnson, M; Moyle, G; Opravil, M; Pelgrom, J; Pozniak, A; Reynes, J; Salgo, M; Vittecoq, D | 1 |
| Butler, KM; Clarke, SM; Condon, S; Healy, CM; Mulcahy, F | 1 |
| Babiker, A; de Rossi, A; Gibb, DM; Grosch-Woerner, I; Klein, N; Newberry, A | 1 |
| Bardsley-Elliot, A; Plosker, GL | 1 |
| Angel, JB; Badley, AD; Cameron, DW; Cassol, S; Chambers, KA; Gallicano, K; Hawley-Foss, N; Kravcik, S; Mandy, F; Parato, K; Phenix, BN | 1 |
| Back, D; Drake, S; Halifax, K; Little, J; Taylor, S | 1 |
| Biollaz, J; Buclin, T; Decosterd, LA; Marzolini, C; Telenti, A | 2 |
| Chapuis, A; Corpataux, JM; Fleury, S; Knabenhans, C; Lazzarin, A; Meuwly, JY; Miedema, F; Pantaleo, G; Rizzardi, GP; Simeoni, E; Tambussi, G | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Lewis, RH; Popescu, M | 1 |
| Rudbeck, G; Schvarcz, R; Söderdahl, G; Ståhle, L | 1 |
| Dudley, MN; Jackson, KA; Kerr, BM; Pithavala, YK; Rosenbaum, SE; Yuen, G | 1 |
| Duncombe, C | 1 |
| Aladdin, H; Dickmeiss, E; Gerstoft, J; Hede, A; Jørgensen, LB; Katzenstein, TL; Nielsen, C; Nielsen, H | 1 |
| Adler, M; Cross, AP; Dunkle, LM; Elion, R; Kaul, S; Kelleher, T; Knupp, C | 1 |
| Chieco-Bianchi, L; De Rossi, A; Del Mistro, A; Giaquinto, C; Zamarchi, R | 1 |
| Akgun, S; Dever, LL; Hutter, D; Ramamoorthy, R | 1 |
| Decker, CF; Martin, GJ; Smith, JH | 1 |
| Atkinson, B; Isaacson, J; Knowles, M; Mazabel, E; Patick, AK | 1 |
| Funk, MB; Hofmann, D; Kreuz, W; Kurowski, M; Linde, R; Schuster, T; Wintergerst, U | 1 |
| Chaput, CC; Frater, AJ; McClure, MO; Weber, JN | 1 |
| Badley, A; Bulman, D; Cameron, DW; Carignan, G; Fyke, K; Gallicano, K; Khaliq, Y; Seguin, I | 1 |
| Israel, DS; Monroe, S; Pakyz, A; Polk, RE; Slain, D | 1 |
| Bryson, YJ; Deville, J; Equils, O; Garratty, E; Krogstad, P; Nielsen, K; Plaeger, S; Sim, MS; Tapia, M; Wei, LS | 1 |
| Condra, JH; Emini, EA; Petropoulos, CJ; Schleif, WA; Shivaprakash, M; Ziermann, R | 1 |
| Abrams, E; Aguayo, R; Bamji, M; Dieudonne, A; Jackson, JB; Johnson, G; Kovacs, A; Krogstad, P; Lee, S; McNamara, J; Mendez, H; Moye, J; Nachman, S; Rana, S; Sever, J; Stanley, K; Wiznia, A | 1 |
| Baldanti, F; Maggiolo, F; Maserati, R; Pan, A; Paolucci, S; Regazzi, MB; Seminari, E; Suter, F; Tinelli, C; Villani, P | 1 |
| Dworkin, MS; Wan, PC | 1 |
| Ammassari, A; Baldini, F; Cingolani, A; De Luca, A; Di Giambenedetto, S; Murri, R | 1 |
| Acosta, E; Cheng, H; Fischl, M; Fiscus, SA; Fletcher, CV; Freimuth, W; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Lagakos, SW; Mills, C; Pettinelli, C; Snyder, S; Swanstrom, R | 1 |
| Gyllensten, K; Sönnerborg, A; Ståhle, L | 1 |
| Clough, LA; Donlon, R; Fiscus, S; Fletcher, CV; Haas, DW; Harris, VL; Johnson, BW; Kates, RE; Larder, B; Lloyd, RM; McKinsey, J; Nicotera, J; Raffanti, S; Schmidt, D; Shoup, RE; Spearman, P; Wilkinson, GR | 1 |
| Tavel, JA | 1 |
| Cabral, S; Fenton, T; Fletcher, CV; Hsia, K; McNamara, J; Mofenson, LM; Spector, SA; Starr, SE; Yong, FH | 1 |
| Aebi, C; Cheseaux, JJ; Kind, C; Lazarevitch, CA; Nadal, D; Rudin, C; Steiner, F | 1 |
| Bulgheroni, E; Chou, TC; Citterio, P; Croce, F; Galli, M; Herrmann, SH; Hirsch, MS; La Seta Catamancio, S; Merrill, DP; Rusconi, S; Yang, OO | 1 |
| Bart, PA; Chapuis, AG; Lazzarin, A; Pantaleo, G; Rizzardi, GP; Tambussi, G | 1 |
| Acosta, EP; Cheng, H; Fischl, M; Fletcher, CV; Gulick, RM; Haubrich, R; Hu, XJ; Katzenstein, D; Mills, C; Raasch, R; Remmel, RP | 1 |
| Apuzzo, L; Deetz, C; Eshleman, SH; Fields, C; Flexner, C; Gallant, JE; Heath-Chiozzi, M; Jackson, JB; Lewis, RH; Raines, CP; Sun, E | 1 |
| Carter, LM; Ellis, BA; Peters, BS; Wolstencroft, RA | 1 |
| Burger, DM; den Hartigh, J; Hoetelmans, RM; Hugen, PW; Kroon, FP; Schippers, EF; Visser, LG | 1 |
| Kehne, SL; Martel, LA; McClernon, DR; McKinney, RE; Valentine, ME; Vavro, CL; Zimmermann, AM | 1 |
| Busch, M; Hecht, FM; Kahn, J; Levy, JA; Martinez-Marino, B; Ong, JC; Stranford, SA | 1 |
| Harrer, T; Helm, M; Korn, K; Kurowski, M; Moschik, B; Paatz, C; Rascu, A; Schmidt, B; Uberla, K; Walter, H | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Soriano, V | 1 |
| Brown, T; Feingold, AR; Meislich, D; Rudy, BJ; Rutstein, RM | 1 |
| Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R | 1 |
| Antela, A; Casado, JL; Dronda, F; García-Arata, I; Hertogs, K; Larder, B; Moreno, S; Pérez-Elías, MJ; Ruiz, L | 1 |
| Bamberger, JD; Chambers, D; Chesney, M; Coates, TJ; Franses, K; Kahn, JO; Katz, MH; Martin, JN; Roland, ME | 1 |
| Hoetelmans, RM; Jurriaans, S; Lange, JM; Mulder, JW; Reijers, MH; Richter, C; Roos, MT; Schuitemaker, H; Sprenger, H; Ten Kate, RW; Ter Hofstede, HJ; Weigel, HM; Weverling, GJ; Wit, FW | 1 |
| Gatell, J; Lazzarin, A; Lundgren, JD; Miller, V; Mocroft, A; Parkin, JM; Phillips, AN; Roge, B; van Lunzen, J; Weber, R | 1 |
| Charpentier, B; Goujard, C; Hafi, A; Paci-Bonaventure, S; Quertainmont, Y; Taburet, AM; Vincent, I | 1 |
| Koranyi, KI; Nahata, MC; Temple, ME | 1 |
| Fournier, S; Maillard, A; Molina, JM | 1 |
| Clendeninn, N; Essunger, P; Markowitz, M; Mittler, J; Perelson, AS; Yuen, GJ | 1 |
| Dubé, MP; Forthal, DN; Haubrich, R; Hellmann, NS; Keiser, PH; Kemper, CA; Leedom, J; Leibowitz, M; Lie, YS; McCutchan, JA; Richman, D; Rigby, A; Smith, DS; Witt, MD | 1 |
| Barreiro, P; González-Lahoz, J; Nuñez, M; Oller, V; Rodríguez-Rosado, R; Soriano, V | 1 |
| Beguinot, I; Bevilacqua, S; Canton, P; Dorvaux, V; May, T; Rabaud, C; Schuhmacher, H | 1 |
| Kravcik, S | 1 |
| Kessler, HA; Nerad, JL | 1 |
| Abraham, PE; Baker, WH; Cushing, HE; Sorensen, SJ | 1 |
| Lalande, M; Mortier, E; Pouchot, J; Vinceneux, P | 1 |
| Freire, E; Todd, MJ; Vega, S; Velazquez-Campoy, A | 1 |
| James, JS | 3 |
| Chapman, S; Peterkin, J; Quart, B; Youle, M | 1 |
| Smart, T | 2 |
| Levin, J | 1 |
| Mascolini, M | 2 |
| Baker, R; Bowers, M | 1 |
| Heidere, C | 1 |
| Friedland, GH; Gulick, RM | 1 |
| Prescott, LM | 1 |
| Fornataro, K; Jefferys, R | 2 |
| Highleyman, L | 1 |
| Gomez, E | 1 |
| Cunningham, S; Eshleman, SH; Jackson, JB; Johnson, G; Krogstad, P; Lee, S; Nachman, S; Palumbo, P; Wang, YG; Wantman, M; Wei, LJ; Wiznia, A | 1 |
| Clark, RA; Kopicko, J; O'Brien, M; Reiss, G | 1 |
| Baede-van Dijk, PA; Burger, DM; Hekster, YA; Hugen, PW; Koopmans, PP; Verweij-van Wissen, CP | 1 |
| Colebunders, R; de Mey, I; Dedes, N; Dreezen, C; Finazzi, R; Florence, E; Koitz, G; Molenberghs, G; Schrooten, W; Youle, M | 1 |
| Merry, C | 1 |
| Funk, MB; Klingebiel, T; Kreuz, W; Linde, R; Notheis, G; Schuster, T; Wintergerst, U | 1 |
| Black, FT; Jensen-Fangel, S; Larsen, L; Obel, N; Thomsen, HF | 1 |
| Cadeo, B; Carosi, G; Fiocchi, C; Marchetti, F; Regazzi, MB; Signorini, L; Viale, P; Villani, A; Villani, P | 1 |
| Becker, MI; Harrigan, PR; Humar, A; Walmsley, SL; Zhang, M | 1 |
| Blanco, JL; Carné, X; Gatell, JM; López-Púa, Y; Mallolas, J; Sarasa-Nacenta, M | 1 |
| Mitchell, SM; Newson, RB; Zambarakji, HJ | 1 |
| Beall, GN; Chang, ES; Liu, YT; Tetreault, DD | 1 |
| Adler, B; James, I; John, M; Mallal, S; McKinnon, E; Nolan, D; Roff, G; Upton, R; Vasikaran, S | 1 |
| Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L | 1 |
| Brundage, RC; Buss, NE; Calles, NR; Craig, C; DeLora, P; Duff, F; Eason, M; Fletcher, CV; Jorga, K; Kline, MW; Schwarzwald, H; Snell, P | 1 |
| Cauda, R; Leone, G; Lucia, MB; Rutella, S; Vella, S | 1 |
| Allan, DA; Behrman, AJ | 1 |
| Gartland, M | 1 |
| Albrecht, MA; Bosch, RJ; Dehlinger, M; Eron, J; Hammer, SM; Katzenstein, DA; Kessler, H; Liou, SH; Para, MF; Valdez, H | 1 |
| Mellors, JW; Montaner, JS | 1 |
| Barnosky, S; Trapé, M | 1 |
| Bartlett, JG; del Rio, C | 1 |
| MacGowan, DJ; Scelsa, SN; Waldron, M | 1 |
| Anderson, R; Chapman, SK; Clendeninn, N; Conant, M; Myers, R; Saag, MS; Sension, M; Tebas, P | 1 |
| Fitzgibbon, JE; Gaur, S; Janahi, M; John, JF; Walsman, SM; Whitley-Williams, P | 1 |
| Borleffs, JC; Boucher, CA; Reedijk, M; Richter, C; Wensing, AM | 1 |
| Boonrod, C; Chuenyam, T; Cooper, DA; Damle, BD; Hassink, EA; Hoetelmans, RM; Lange, JM; Limpongsanurak, S; Phanuphak, P; Rongkavilit, C; Ruxrungtham, K; Srigritsanapol, A; Thaithumyanon, P | 1 |
| Becker, MI; Britto, P; Capparelli, EV; Connor, JD; Graham, B; Holland, D; Luzuriaga, K; Mofenson, L; Smith, E; Sullivan, JL | 1 |
| Pereira, A; Taylor, S | 1 |
| Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Moreno, A; Moreno, S; Perez-Elías, MJ | 1 |
| Bower, M; Gazzard, BG; Johnson, MA; Lampe, F; Mandalia, S; Matthews, GV; Nelson, MR; Phillips, AN; Sabin, CA | 1 |
| Carriero, PL; Marubbi, F; Maserati, R; Montagna, M; Regazzi, MB; Seminari, E; Villani, P | 1 |
| Barbour, JD; Deeks, SG; Grant, RM; Martin, JN | 1 |
| Back, DJ; Buclin, T; Chave, JP; Decosterd, LA; Eap, CB; Fellay, J; Furrer, H; Marzolini, C; Meaden, ER; Opravil, M; Pantaleo, G; Retelska, D; Ruiz, L; Schinkel, AH; Telenti, A; Vernazza, P | 1 |
| Belohradsky, BH; Eberle, J; Engelhorn, C; Funk, M; Hoffmann, F; Notheis, G; Wintergerst, U | 1 |
| Jaccard, R; Jenni, R; Opravil, M; Speich, R | 1 |
| Abrams, DI; Aweeka, FT; Benowitz, NL; Hilton, JF; Kosel, BW; Lizak, PS; Shade, SB | 1 |
| Aguayo, R; Dieudonne, A; Jackson, JB; Johnson, G; Khoury, M; Krogstad, P; Lee, S; McNamara, J; Mendez, H; Moye, J; Nachman, S; Stanley, K; Wiznia, A | 1 |
| Burger, DM; de Groot, R; Geelen, SP; Hartwig, NG; Hop, WC; Osterhaus, AD; Scherpbier, HJ; Schutten, M; van Lochem, EG; van Rossum, AM; Weemaes, CM; Wolfs, TF | 1 |
| Korach, M; Leclercq, P; Leverve, X; Péronnet, F | 1 |
| de Groot, R; Fraaij, PL; van Rossum, AM | 1 |
| Brundage, RC; Calles, NR; Delora, P; Duff, F; Fletcher, CV; Grub, S; Jorga, K; Kline, MW; Lüdin, E; Schwarzwald, H | 1 |
| Beardsell, A; Braitstein, P; Chan, K; Hogg, RS; McLeod, A; Montaner, JS; O'Shaughnessy, MV | 2 |
| Kroll, H; Ndagijimana, JM; Niehues, T | 1 |
| Boonrod, C; Chuenyam, T; Cooper, DA; Hassink, EA; Hoetelmans, RM; Lange, JM; Limpongsanurak, S; Phanuphak, P; Rongkavilit, C; Ruxrungtham, K; Srigritsanapol, A; Thaithumyanon, P; Ubolyam, S; van Heeswijk, RP | 1 |
| Klinowska-Skupniewska, J; Prandota-Schoepp, A | 1 |
| Ray, SC; Sulkowski, MS; Thomas, DL | 1 |
| Christopherson, C; Fenton, T; Fletcher, CV; Hsia, K; Powell, CA; Saitoh, A; Spector, SA; Starr, SE | 1 |
| Hasegawa, H; Hattori, T; Ishikawa, M; Kaku, M; Kikuchi, M; Ohno, I; Okada, S | 1 |
| Carosi, G; Carriero, PL; Castagna, A; Castelli, F; Danise, A; Giudici, B; Lazzarin, A; Paraninfo, G | 1 |
| Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K | 1 |
| Bartlett, JA; Bucy, RP; Fiscus, SA; Gryszowska, V; Miralles, GD; Ottinger, J; Pruitt, SK; Sevin, AD; Silberman, M | 1 |
| Beylot, J; Bonarek, M; Bonnet, F; de Witte, S; Lamarque, P; Morlat, P; Receveur, MC | 1 |
| Choo, PW; Colson, AE; Keller, MJ; Pettus, PT; Platt, R; Sax, PE | 1 |
| Hammer, SM | 1 |
| Arribas, J; Beall, G; Bernstein, B; Brun, S; Japour, A; Johnson, D; Johnson, M; King, M; Lalonde, R; Ruane, P; Sun, E; Walmsley, S | 1 |
| Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ | 1 |
33 review(s) available for nelfinavir and HIV Infections
| Article | Year |
|---|---|
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2013 |
Antiretroviral therapy response among HIV-2 infected patients: a systematic review.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Female; HIV Infections; HIV-2; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Ritonavir; Treatment Outcome | 2014 |
A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2009 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Hepatotoxicity and nelfinavir: a meta-analysis.
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Liver; Nelfinavir | 2005 |
Nelfinavir: a review of its use in the management of HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; Humans; Molecular Structure; Nelfinavir; Pregnancy; Salvage Therapy; Treatment Outcome | 2005 |
A review of nelfinavir for the treatment of HIV infection.
Topics: Female; HIV Infections; Humans; Molecular Structure; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Treatment Outcome | 2006 |
HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo.
Topics: Animals; Apoptosis; Hippocampus; HIV Infections; HIV Protease Inhibitors; Humans; Mitochondrial ADP, ATP Translocases; Nelfinavir; Pancreatitis; Ritonavir; Signal Transduction; Stroke; T-Lymphocytes | 2007 |
HIV-1 protease inhibitors. A review for clinicians.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Nelfinavir; Ritonavir; Saquinavir; Viral Load | 1997 |
Nelfinavir.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Male; Nelfinavir; Sulfonic Acids | 1997 |
A 'second life' agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Attitude to Health; Drug Approval; Drug Costs; Drug Interactions; Health Policy; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Life Style; Nelfinavir; Primary Prevention; Ritonavir; Saquinavir; United States; United States Food and Drug Administration; Viral Load | 1997 |
Nelfinavir. A review of its therapeutic efficacy in HIV infection.
Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Drug Tolerance; HIV; HIV Infections; Humans; Nelfinavir | 1998 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Retina; Retinal Diseases; Ritonavir; Saquinavir | 1998 |
Development of HIV protease inhibitors: a survey.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Structure-Activity Relationship | 1998 |
Simultaneous use of two protease inhibitors in HIV infection.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Drug interactions of HIV protease inhibitors.
Topics: Anti-Infective Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
Nelfinavir mesylate: a protease inhibitor.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 1999 |
HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Topics: Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Lipodystrophy; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Combined treatment with zidovudine, lamivudine, nelfinavir and ganciclovir in an infant with human immunodeficiency virus type 1 infection and cytomegalovirus encephalitis: case report and review of the literature.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cytomegalovirus Infections; Diseases in Twins; Drug Therapy, Combination; Encephalitis, Viral; Female; Ganciclovir; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Lamivudine; Nelfinavir; Zidovudine | 1999 |
Nelfinavir, a new protease inhibitor: early clinical results.
Topics: Clinical Trials as Topic; Disease Management; Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Paediatric treatment issues.
Topics: Administration, Oral; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Oxazines | 1999 |
[Early treatment of sexual exposure to human immunodeficiency virus].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Nelfinavir; Probability; Risk Factors; Sexual Behavior; Sexual Partners; Time Factors; Zidovudine | 2000 |
Nelfinavir: an update on its use in HIV infection.
Topics: Adult; Area Under Curve; Biological Availability; Child; Drug Interactions; Drug Therapy, Combination; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Metabolic Clearance Rate; Nelfinavir; Patient Compliance; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tissue Distribution; Virus Replication | 2000 |
The choice of HIV protease inhibitor: indinavir is currently the best option.
Topics: Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Treatment Outcome | 1999 |
Ongoing trials in HIV protease inhibitors.
Topics: Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; United States; United States Food and Drug Administration | 2000 |
Nelfinavir mesylate.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 2000 |
Pharmacology and clinical experience with saquinavir.
Topics: Biological Availability; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Virus Replication | 2001 |
[Resistance to protease inhibitors].
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Penetration of HIV-1 protease inhibitors into CSF and semen.
Topics: Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Ritonavir; Saquinavir; Semen; Sulfonamides; Viral Load | 2000 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir | 2002 |
Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.
Topics: Adolescent; Area Under Curve; Blood Proteins; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Randomized Controlled Trials as Topic; Saquinavir | 2002 |
151 trial(s) available for nelfinavir and HIV Infections
| Article | Year |
|---|---|
Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2.
Topics: Animals; Antiviral Agents; China; COVID-19; Female; HIV Infections; Humans; Macaca mulatta; Nelfinavir; Pregnancy; Prospective Studies; SARS-CoV-2 | 2023 |
Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
Topics: COVID-19 Drug Treatment; COVID-19 Vaccines; Female; HIV Infections; Humans; Japan; Male; Middle Aged; Multicenter Studies as Topic; Nelfinavir; Pregnancy; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome | 2021 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.
Topics: Adult; Area Under Curve; beta Carotene; Dietary Supplements; Drug Stability; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nelfinavir; Viral Load | 2012 |
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant Formula; Infant, Newborn; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Lamivudine; Male; Nelfinavir; Nevirapine; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 2012 |
Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Multivariate Analysis; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2002 |
The pharmacokinetics of nelfinavir in HIV-1-infected children.
Topics: Administration, Oral; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Nelfinavir; Powders; Stavudine; Tablets | 2002 |
Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Nelfinavir; Patient Compliance; RNA, Viral; Viral Load | 2002 |
Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.
Topics: Antiviral Agents; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral | 2002 |
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interferon-gamma; Interleukin-10; Interleukin-2; Male; Nelfinavir; Oxazines; Random Allocation; RNA, Messenger; Stavudine; Treatment Failure | 2002 |
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Argentina; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Spain; Treatment Outcome; Zidovudine | 2002 |
The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
Topics: CD4 Lymphocyte Count; Child, Preschool; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; Thailand; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Efavirenz liquid formulation in human immunodeficiency virus-infected children.
Topics: Administration, Oral; Alkynes; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Oxazines; RNA, Viral; Sensitivity and Specificity; Severity of Illness Index; Single-Blind Method; Survival Analysis; Treatment Outcome; Viral Load | 2002 |
Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
Topics: Adult; Area Under Curve; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir | 2002 |
High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients.
Topics: Body Composition; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipodystrophy; Male; Middle Aged; Nelfinavir; Risk Factors | 2002 |
Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nelfinavir; Stavudine; Tablets, Enteric-Coated | 2002 |
Diurnal variation of plasma protease inhibitor concentrations.
Topics: Circadian Rhythm; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Saquinavir | 2002 |
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
Topics: Adult; Atazanavir Sulfate; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Nelfinavir; Oligopeptides; Pyridines; RNA, Viral; Stavudine; Time Factors; Viral Load | 2003 |
The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Calcium Carbonate; Calcium Gluconate; Chronic Disease; Diarrhea; Drug Combinations; Drug Interactions; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nelfinavir; Pilot Projects; Prospective Studies; Severity of Illness Index | 2003 |
Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Topics: Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Male; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine | 2003 |
Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Multivariate Analysis; Nelfinavir; Patient Compliance; Reverse Transcriptase Inhibitors; RNA, Viral; Surveys and Questionnaires; Viral Load | 2003 |
Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors.
Topics: Antiretroviral Therapy, Highly Active; Body Height; Body Mass Index; CD4 Lymphocyte Count; Child, Preschool; Female; Growth; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydrocortisone; Infant; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Male; Nelfinavir; Serum Albumin; Thyroxine; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Viral Load | 2003 |
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Cohort Studies; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Middle Aged; Mutation; Nelfinavir; Nevirapine; Phenotype; Reverse Transcriptase Inhibitors; Spain; Treatment Failure; Zidovudine | 2003 |
Sildenafil does not alter nelfinavir pharmacokinetics.
Topics: Adult; Area Under Curve; Chromatography, High Pressure Liquid; Drug Interactions; Drug Therapy, Combination; Erectile Dysfunction; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Piperazines; Purines; Ritonavir; Saquinavir; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2003 |
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Organophosphonates; Oxazines; Treatment Failure | 2003 |
Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Cross-Sectional Studies; Drug Monitoring; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; RNA, Viral | 2003 |
Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Prospective Studies; RNA, Viral; Viral Load; Zidovudine | 2003 |
Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
Topics: Anti-HIV Agents; Capsules; CD4 Lymphocyte Count; Drug Therapy, Combination; Follow-Up Studies; Gelatin; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Reverse Transcriptase Inhibitors; Saquinavir; Time Factors; Treatment Outcome; Virus Replication | 2003 |
Prospective comparison of first-line nelfinavir therapy versus nelfinavir introduction in rescue antiretroviral regimens.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infections; Nelfinavir; Prospective Studies; RNA, Viral; Salvage Therapy; Transcription Factors | 2003 |
Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Zidovudine | 2003 |
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Prospective Studies; Viral Load | 2003 |
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Indinavir; Male; Nelfinavir; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2003 |
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.
Topics: Administration, Oral; Cannabinoids; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dronabinol; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; RNA, Viral; Viral Load | 2003 |
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Male; Middle Aged; Nelfinavir; Nervous System Diseases; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Outcome | 2003 |
R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.
Topics: Adult; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Polymorphism, Genetic; Predictive Value of Tests; RNA, Viral; Treatment Failure | 2003 |
A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.
Topics: Adult; Anti-HIV Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Energy Metabolism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Insulin; Male; Middle Aged; Nelfinavir; Nevirapine; Triglycerides | 2003 |
[Immunological, virological and clinical response in patients infected with HIV after highly active antiviral therapy with nelfinavir: prospective cohort study].
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Prospective Studies | 2003 |
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Oxazines; RNA, Viral; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nelfinavir; Oxazines; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.
Topics: Acidosis, Lactic; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol, LDL; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Oligopeptides; Pyridines; RNA, Viral; Stavudine; Treatment Outcome; Triglycerides | 2003 |
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Topics: Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Global Health; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Nelfinavir; Patient Compliance; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; Viral Load | 2004 |
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Organophosphates; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides | 2004 |
A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir | 2003 |
Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Blotting, Western; Female; Half-Life; HIV Infections; Humans; Indinavir; Male; Nelfinavir | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Sex Factors | 2004 |
Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Male; Nelfinavir; Prospective Studies; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2004 |
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Topics: Cohort Studies; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Molecular Sequence Data; Mutation; Nelfinavir; Polymorphism, Genetic; RNA, Viral; Viral Plaque Assay; Virus Replication | 2004 |
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cholesterol; Cholesterol, LDL; Female; HIV Infections; Humans; Hyperlipidemias; Lamivudine; Lipids; Male; Nelfinavir; Oligopeptides; Pyridines; RNA, Viral; Safety; Stavudine; Time Factors; Triglycerides | 2004 |
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Newborn; Liver Failure, Acute; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Safety; Stevens-Johnson Syndrome | 2004 |
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Nelfinavir; Predictive Value of Tests; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral; Sex Characteristics; Stavudine; Viral Load | 2004 |
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nelfinavir; Organophosphates; Patient Compliance; Ritonavir; Sulfonamides | 2004 |
HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Phenotype; Stavudine; Treatment Failure; Zidovudine | 2004 |
Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD4 Lymphocyte Count; Cell Transformation, Viral; Genes, MDR; Herpesvirus 4, Human; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Japan; Lymphocytes; Nelfinavir; Polymorphism, Single Nucleotide | 2004 |
Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Topics: Aging; Bayes Theorem; Body Weight; Chromatography, High Pressure Liquid; Didanosine; Drug Interactions; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Models, Biological; Nelfinavir; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Stavudine | 2005 |
Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Liver Cirrhosis; Male; Middle Aged; Nelfinavir; Quality Control; Spectrophotometry, Ultraviolet | 2005 |
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Female; HIV Infections; Humans; Hyperlipidemias; Lamivudine; Life Expectancy; Male; Markov Chains; Middle Aged; Nelfinavir; Oligopeptides; Pyridines; Risk Factors; Stavudine | 2005 |
Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations.
Topics: CD4 Lymphocyte Count; Diarrhea; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Patient Satisfaction; Tablets; Viral Load | 2005 |
Lopinavir/r versus nelfinavir as salvage therapy.
Topics: Child; Child, Preschool; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Nelfinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Salvage Therapy; Viral Load | 2005 |
The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors | 2005 |
Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
Topics: Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Odds Ratio; Patient Compliance; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral; Viral Load | 2005 |
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; HIV Infections; Humans; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Male; Middle Aged; Nelfinavir; Prospective Studies; Ritonavir; Viral Load | 2005 |
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; RNA, Viral; Viral Load | 2005 |
Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Models, Chemical; Nelfinavir; Prospective Studies | 2005 |
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Outcome | 2005 |
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Cyclopropanes; Drug Therapy, Combination; Dyslipidemias; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Lipids; Male; Nelfinavir; Nucleosides; Oxazines | 2005 |
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.
Topics: Adult; Alkynes; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme System; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Oxazines; Pharmacogenetics; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2005 |
Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunosuppression Therapy; Nelfinavir; Saquinavir; Viral Load | 2005 |
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Multicenter Studies as Topic; Nelfinavir; Patient Compliance; Prospective Studies; Ritonavir; Viral Load | 2005 |
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; CD4 Lymphocyte Count; Cholesterol; Dideoxynucleosides; Drug Combinations; Female; Hispanic or Latino; HIV Infections; HIV-1; Humans; Hyperlipidemias; Lactic Acid; Lamivudine; Male; Nelfinavir; Nevirapine; Prospective Studies; Sex Factors; Stavudine; Treatment Outcome; Triglycerides; Zidovudine | 2006 |
In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apoptosis; Cross-Sectional Studies; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Mitochondria; Nelfinavir; Protease Inhibitors | 2005 |
Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Male; Nelfinavir; Prospective Studies; Viral Load | 2006 |
Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Injections; Medroxyprogesterone Acetate; Middle Aged; Nelfinavir; Nevirapine; Ovulation Inhibition; Oxazines; Progesterone; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors | 2007 |
A virological benefit from an induction/maintenance strategy: the Forte trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Patient Compliance; Remission Induction; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Time Factors; Treatment Failure; United Kingdom; Viral Load | 2007 |
Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Isoniazid; Male; Nelfinavir; Prospective Studies; Rifabutin; Tuberculosis | 2007 |
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Didanosine; Double-Blind Method; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Nelfinavir; Prospective Studies; Stavudine; Testosterone; Zidovudine | 2007 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.
Topics: Administration, Oral; Adolescent; Alkynes; Area Under Curve; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Metabolic Clearance Rate; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; United States; Virus Replication | 2008 |
Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Models, Biological; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine; Tissue Distribution; Zidovudine | 2007 |
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Female; Graft Rejection; Half-Life; Hepatitis C; HIV; HIV Infections; Humans; Liver Transplantation; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Tacrolimus; Viral Load | 2007 |
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Constitution; Cardiovascular Diseases; Cyclopropanes; Diabetes Mellitus, Type 2; Disease Progression; Epidemiologic Methods; Female; HIV Infections; Humans; Male; Metabolic Syndrome; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors | 2007 |
Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Contraceptive Agents, Female; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Injections, Intramuscular; Medroxyprogesterone Acetate; Nelfinavir; Nevirapine; Ovulation Inhibition; RNA, Viral; Safety; Viral Load | 2008 |
Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance.
Topics: Drug Resistance, Microbial; Genes, env; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Ritonavir; Viremia | 1998 |
A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Evaluation; Drug Resistance, Microbial; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; RNA, Viral | 1998 |
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; RNA, Viral; Saquinavir | 1998 |
Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus.
Topics: Adolescent; Adult; Anti-HIV Agents; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir | 1998 |
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Pilot Projects; Saquinavir; Stavudine; Treatment Outcome; Viral Load | 1998 |
Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Topics: Adult; Anti-HIV Agents; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Saquinavir; Treatment Outcome; Viral Load; Viremia | 1999 |
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Predictive Value of Tests; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Treatment Failure; Viral Load | 1999 |
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
Topics: Adult; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir | 1999 |
Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Reverse Transcriptase Inhibitors; Salvage Therapy; Saquinavir; Stavudine; Viral Load | 1999 |
Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral | 1999 |
Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy.
Topics: Adult; Antiviral Agents; Apoptosis; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Fas Ligand Protein; HIV Infections; HIV Protease Inhibitors; Humans; Lymphocyte Count; Membrane Glycoproteins; Nelfinavir; Retroviridae; RNA, Viral; Signal Transduction; T-Lymphocytes; Time Factors; Viral Load | 1999 |
Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zidovudine | 1999 |
Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Nelfinavir; Oxazines; Spectrophotometry, Ultraviolet | 1999 |
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Topics: Adolescent; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral | 1999 |
Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Chromatography, High Pressure Liquid; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nelfinavir; Oxazines; Stavudine | 2000 |
A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients.
Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Kidney Diseases; Lamivudine; Male; Nelfinavir; Patient Compliance; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome | 2000 |
Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Viral Load | 2000 |
dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Nelfinavir; Nevirapine; Research Design; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine | 1998 |
Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine | 1998 |
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Pregnancy; RNA, Viral; Saquinavir | 2000 |
Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Seronegativity; Humans; Kinetics; Lymph Nodes; Lymphocyte Activation; Middle Aged; Nelfinavir; Regression Analysis; Saquinavir; T-Lymphocyte Subsets; T-Lymphocytes; Time Factors | 2000 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial.
Topics: Adult; Demography; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir | 2000 |
The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Topics: Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; RNA, Viral; Safety; Stavudine; Treatment Outcome; Viral Load | 1999 |
Variability in activity of hepatic CYP3A4 in patients infected with HIV.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; HIV Infections; Humans; Indinavir; Liver; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir | 2000 |
Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.
Topics: Adolescent; CD4-Positive T-Lymphocytes; Cell Differentiation; Child; Coculture Techniques; Female; HIV Infections; HIV-1; Humans; Immunophenotyping; Infant; Lamivudine; Leukocytes, Mononuclear; Male; Nelfinavir; Prospective Studies; Receptors, CCR5; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Virus Replication; Zidovudine | 2000 |
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Phenotype; Protein Binding; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clin
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Ethnicity; Female; HIV Infections; Humans; Infant; Male; Nelfinavir; Nevirapine; Puerto Rico; Racial Groups; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; United States; Viral Load | 2000 |
Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine | 1999 |
Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Topics: Adult; Anticholesteremic Agents; Drug Tolerance; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Pilot Projects; Pravastatin; Ritonavir; Saquinavir; Treatment Outcome | 2000 |
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nelfinavir; Organophosphonates; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir | 2000 |
Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.
Topics: Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Messenger; RNA, Viral | 2000 |
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Topics: Adult; Anti-HIV Agents; Antigens, Fungal; Antigens, Viral; Antiretroviral Therapy, Highly Active; Candida albicans; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Cytomegalovirus; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Simplexvirus; Sulfonamides; T-Lymphocyte Subsets | 2000 |
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 2000 |
Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy.
Topics: Anti-HIV Agents; Child; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lymphocyte Subsets; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Time Factors; Viral Load | 2000 |
Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.
Topics: Amino Acid Sequence; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Microbial; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Molecular Sequence Data; Nelfinavir; Phenotype; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Treatment Outcome; Viral Load | 2000 |
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Failure; Viral Load | 2001 |
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Time Factors; Treatment Outcome; Viral Load | 2001 |
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Prospective Studies; Ritonavir; Saquinavir; Treatment Outcome; Viral Load | 2001 |
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Ritonavir; Sample Size; Saquinavir; Stavudine; Zidovudine | 2001 |
Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Spain; Treatment Failure; Viral Load; Virus Replication | 2001 |
Phase II/III Trials of Viracept start.
Topics: Anti-HIV Agents; Blood; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; Stavudine; Sulfonic Acids; Time Factors; Zidovudine | 1996 |
Early results from SPICE study reported.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Europe; HIV Infections; Humans; Nelfinavir; Nucleosides; Saquinavir; Treatment Outcome | 1998 |
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Mutation; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Treatment Failure; Viral Load | 2001 |
Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nelfinavir; Nevirapine; Oxazines; Prospective Studies; Salvage Therapy | 2001 |
Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aryl Hydrocarbon Hydroxylases; Body Weight; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Databases, Factual; Diarrhea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Omeprazole | 2001 |
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.
Topics: Adult; Antiretroviral Therapy, Highly Active; Erectile Dysfunction; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Multivariate Analysis; Nelfinavir; Prevalence; Risk Factors; Ritonavir; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 2001 |
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
Topics: Adolescent; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Time; Viral Load; Zidovudine | 2001 |
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nelfinavir; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral | 2001 |
Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy.
Topics: Administration, Oral; Alkynes; Anti-HIV Agents; Anti-Infective Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Levofloxacin; Nelfinavir; Ofloxacin; Oxazines; Prospective Studies | 2001 |
AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Clinical Protocols; Diarrhea; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nausea; Nelfinavir; Patient Compliance; RNA, Viral; Zidovudine | 2001 |
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Mutation; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Treatment Failure; Viral Load | 2001 |
Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2001 |
Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome; Triglycerides | 2001 |
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
Topics: Anti-HIV Agents; Area Under Curve; Didanosine; DNA, Viral; Drug Interactions; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Infant; Infant, Newborn; Nelfinavir; Radioimmunoassay; Reverse Transcriptase Polymerase Chain Reaction; Stavudine | 2001 |
Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral | 2001 |
Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.
Topics: Adult; Aged; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease; HIV-1; Humans; Male; Middle Aged; Mutation; Nelfinavir; Prospective Studies; Protease Inhibitors; Reverse Transcriptase Inhibitors; Salvage Therapy; Saquinavir; Treatment Outcome; Viral Load | 2002 |
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2002 |
Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile.
Topics: Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Excipients; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kinetics; Male; Nelfinavir; Patient Compliance; Tablets; Therapeutic Equivalency | 2001 |
The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.
Topics: Adult; Appetite Stimulants; Dronabinol; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Marijuana Smoking; Middle Aged; Nelfinavir | 2002 |
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine | 2002 |
Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.
Topics: Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Netherlands; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine | 2002 |
Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2002 |
Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Topics: Adult; Anti-HIV Agents; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infant, Newborn; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome | 2002 |
Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Child; Child, Preschool; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Leukocytes, Mononuclear; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2002 |
Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
Topics: Adolescent; Adult; CD4 Lymphocyte Count; Cyclophosphamide; DNA, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lymphoid Tissue; Male; Middle Aged; Monocytes; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Viral Load | 2002 |
HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors | 2002 |
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nelfinavir; Proportional Hazards Models; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Survival Analysis; Viral Load | 2002 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2002 |
360 other study(ies) available for nelfinavir and HIV Infections
| Article | Year |
|---|---|
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication | 2007 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
Topics: Antiviral Agents; Cell Line; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans | 2008 |
HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cell Line; Cells, Cultured; Codon; Genotype; HIV Infections; HIV Protease; HIV-1; Humans; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Pyrimidinones | 2010 |
Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Biological Availability; Caco-2 Cells; CCR5 Receptor Antagonists; HIV Infections; HIV-1; Humans; Piperazines; Rats; Receptors, CCR5 | 2010 |
Potential Tools for Eradicating HIV Reservoirs in the Brain: Development of Trojan Horse Prodrugs for the Inhibition of P-Glycoprotein with Anti-HIV-1 Activity.
Topics: Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Cell Line; Dimerization; Drug Development; HIV Infections; HIV-1; Humans; Models, Molecular; Prodrugs | 2020 |
Molecular basis for reduced cleavage activity and drug resistance in D30N HIV-1 protease.
Topics: Acquired Immunodeficiency Syndrome; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Mutation; Nelfinavir | 2022 |
HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
Topics: Animals; COVID-19 Drug Treatment; Cricetinae; HIV Infections; HIV Protease Inhibitors; Lopinavir; Lung; Mesocricetus; Nelfinavir; Ritonavir; RNA, Viral; SARS-CoV-2 | 2022 |
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Contraceptive Agents, Hormonal; Contraceptive Effectiveness; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Lopinavir; Medroxyprogesterone Acetate; Nelfinavir; Rifampin; Ritonavir; Tuberculosis | 2021 |
Systems Pharmacology Identifies an Arterial Wall Regulatory Gene Network Mediating Coronary Artery Disease Side Effects of Antiretroviral Therapy.
Topics: Anti-Retroviral Agents; Arteries; Atherosclerosis; Cholesterol Esters; Coronary Artery Disease; Databases, Nucleic Acid; DNA-Binding Proteins; Foam Cells; Gene Regulatory Networks; HIV Infections; Humans; Macrophages; Nelfinavir; Ritonavir; Saquinavir; THP-1 Cells | 2019 |
Sequence variability in p6 gag protein and gag/pol coevolution in human immunodeficiency type 1 subtype F genomes.
Topics: Amino Acid Sequence; Drug Resistance, Viral; Evolution, Molecular; gag Gene Products, Human Immunodeficiency Virus; Genes, gag; Genes, pol; Genetic Variation; Genome, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Molecular Sequence Data; Mutation; Nelfinavir | 2013 |
Cycloviolacin O2 (CyO2) suppresses productive infection and augments the antiviral efficacy of nelfinavir in HIV-1 infected monocytic cells.
Topics: Antiviral Agents; Cell Line; HIV Infections; HIV-1; Humans; Monocytes; Nelfinavir | 2013 |
HIV-1 protease-substrate coevolution in nelfinavir resistance.
Topics: Crystallography, X-Ray; Drug Resistance, Viral; Evolution, Molecular; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Nelfinavir; Peptide Fragments; Protein Conformation; Substrate Specificity | 2014 |
Novel nelfinavir mesylate loaded d-α-tocopheryl polyethylene glycol 1000 succinate micelles for enhanced pediatric anti HIV therapy: In vitro characterization and in vivo evaluation.
Topics: Animals; Anti-HIV Agents; HIV Infections; Male; Micelles; Nelfinavir; Rats; Rats, Wistar; Vitamin E | 2014 |
Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Case-Control Studies; Coinfection; Didanosine; Female; Hepatitis C; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Liver Cirrhosis; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Time Factors | 2015 |
Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy.
Topics: Adult; CD4-Positive T-Lymphocytes; Cohort Studies; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Mothers; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Prevalence; Risk Factors; Young Adult | 2016 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Topics: Binding Sites; Catalytic Domain; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Nelfinavir; Thermodynamics | 2015 |
Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4.
Topics: Amphetamine-Related Disorders; Atazanavir Sulfate; Catalytic Domain; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Inactivation, Metabolic; Lopinavir; Methamphetamine; Microsomes, Liver; Molecular Docking Simulation; Nelfinavir; Protein Binding; Pyridines; Pyrones; Sulfonamides | 2016 |
Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?
Topics: Adult; Carcinogens; Cohort Studies; Drug Contamination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Male; Middle Aged; Nelfinavir; Neoplasms; Risk Assessment | 2016 |
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
Topics: Adult; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Models, Biological; Mutation; Nelfinavir; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Failure; Viral Load; Zidovudine | 2008 |
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Viral Load; Young Adult | 2008 |
Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.
Topics: Adult; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Nelfinavir; Organophosphates; Sulfonamides; Tacrolimus | 2008 |
Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.
Topics: Adolescent; Adult; Area Under Curve; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Puerperal Infection; RNA, Viral; Viral Load; Young Adult | 2008 |
Effectiveness of commercial inhibitors against subtype F HIV-1 protease.
Topics: Amino Acid Sequence; Binding Sites; Drug Resistance, Viral; Enzyme Activation; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Kinetics; Microbial Viability; Molecular Sequence Data; Mutation; Nelfinavir; Polymorphism, Genetic; Ritonavir; Sequence Alignment | 2009 |
Bullous skin eruption in an HIV patient during antiretroviral drugs therapy.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nelfinavir; Skin Diseases, Vesiculobullous | 2008 |
Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes--relevance for partial lipodystrophy.
Topics: Adipocytes, White; Adipogenesis; Adipose Tissue; Animals; Antiretroviral Therapy, Highly Active; Body Fat Distribution; Cell Differentiation; Cell Line; Gene Expression Regulation; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Mice; Nelfinavir; Organ Specificity; Rats; Rats, Sprague-Dawley | 2009 |
Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation, Missense; Nelfinavir; Portugal; Saquinavir; Selection, Genetic | 2009 |
The influence of the patients' educational levels on socioeconomic, clinical, immunological and virological endpoints.
Topics: Adolescent; Adult; Aged; CD4 Lymphocyte Count; Educational Status; Female; Health Knowledge, Attitudes, Practice; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Regression Analysis; Socioeconomic Factors; Viral Load; Young Adult | 2009 |
Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.
Topics: Adult; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mutation, Missense; Nelfinavir; Phylogeny; Point Mutation; Pregnancy; Pregnancy Complications, Infectious; Selection, Genetic; Zidovudine | 2009 |
Antiretroviral compounds and cholesterol efflux from macrophages.
Topics: Animals; Anti-Retroviral Agents; Apoptosis; Cell Line; Cholesterol; Cholesterol, HDL; HIV Infections; Humans; Macrophages; Mice; Nelfinavir; Ritonavir | 2009 |
The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients.
Topics: Adult; Anticarcinogenic Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk | 2009 |
Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection: the VIRAKINETICS II study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Plasma | 2009 |
Fulminant hepatic failure associated with antiretroviral therapy in a pregnant woman.
Topics: Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Infant, Newborn; Liver Failure, Acute; Liver Transplantation; Male; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Protease Inhibitors; Young Adult | 2009 |
CD4 responses in the setting or suboptimal virological responses to antiretroviral therapy: features, outcomes, and associated factors.
Topics: Adult; CD4 Antigens; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Treatment Outcome; Viral Load | 2009 |
CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2C19; Gene Expression Regulation; Gene Frequency; Genetic Predisposition to Disease; Genetic Variation; Genotype; HIV Infections; HIV-1; Humans; Nelfinavir; Retrospective Studies; RNA, Viral; Treatment Outcome | 2010 |
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 2010 |
Effects of antiretroviral drug recall on perception of therapy benefits and on adherence to antiretroviral treatment in HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Recalls; Female; HIV Infections; Humans; Male; Nelfinavir; Patient Compliance | 2009 |
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birth Weight; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Lopinavir; Maternal-Fetal Exchange; Nelfinavir; Nevirapine; Oligopeptides; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Pyrimidinones | 2009 |
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2010 |
Marked tumor response and fatal hemoptysis during radiation for lung cancer in a human immunodeficiency virus-positive patient taking nelfinavir.
Topics: Carcinoma, Squamous Cell; Fatal Outcome; Hemoptysis; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lung Neoplasms; Male; Nelfinavir | 2009 |
HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro.
Topics: Antimalarials; Artemisinins; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Malaria; Nelfinavir | 2010 |
Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp.
Topics: Animals; Aspartic Acid Proteases; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Leishmania infantum; Leishmania mexicana; Leishmaniasis; Macrophages; Mice; Monocytes; Nelfinavir; Saquinavir | 2010 |
Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chemoprevention; Drug Therapy, Combination; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Netherlands; Oligopeptides; Patient Compliance; Pyridines; Reverse Transcriptase Inhibitors; Sexual Behavior; Young Adult | 2010 |
Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV-1; Humans; Mutation; Nelfinavir; Treatment Failure | 2010 |
Effect of ethanol on spectral binding, inhibition, and activity of CYP3A4 with an antiretroviral drug nelfinavir.
Topics: Alcoholism; Anti-Retroviral Agents; Binding Sites; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Ethanol; HIV Infections; Humans; Inactivation, Metabolic; Liver; Nelfinavir; Protein Binding | 2010 |
Genetic diversity of HIV type 1 in Montenegro.
Topics: Adult; Antiretroviral Therapy, Highly Active; Base Sequence; Drug Resistance, Viral; Female; Genetic Variation; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Montenegro; Nelfinavir; Phylogeny; Population Surveillance | 2011 |
Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cohort Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nelfinavir; Proton Pump Inhibitors; Registries; Retrospective Studies; Risk; Risk Factors; Time Factors; Viral Load | 2011 |
Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.
Topics: Anti-HIV Agents; Area Under Curve; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nelfinavir; Viral Load | 2011 |
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Nelfinavir; Nevirapine; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Selection, Genetic | 2011 |
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Topics: Antibiotics, Antineoplastic; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Sarcoma, Kaposi; Treatment Outcome | 2011 |
Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.
Topics: Acyclovir; Administration, Topical; Adult; Aminoquinolines; Antiviral Agents; Drug Resistance, Viral; Foscarnet; Herpes Simplex; HIV Infections; HIV-1; Humans; Imiquimod; Lamivudine; Male; Middle Aged; Nelfinavir; Simplexvirus; Zidovudine | 2012 |
The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
Topics: Amino Acid Substitution; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Virus Cultivation | 2012 |
Transplacental passage of nevirapine, nelfinavir and lopinavir.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; Fetal Blood; HIV Infections; Humans; Lopinavir; Maternal-Fetal Exchange; Nelfinavir; Nevirapine; Pregnancy | 2012 |
Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission.
Topics: Adult; Aging, Premature; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Female; HIV Infections; Humans; Hyperbilirubinemia; Infant, Newborn; Infectious Disease Transmission, Vertical; Kenya; Nelfinavir; Nevirapine; Pregnancy | 2012 |
Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Cytidine Triphosphate; Dideoxynucleotides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Phosphorylation; Real-Time Polymerase Chain Reaction; Ritonavir; RNA, Messenger; Tandem Mass Spectrometry; Transfection; Young Adult | 2013 |
Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients.
Topics: Antiprotozoal Agents; Aspartic Acid Proteases; Colorimetry; Fluorometry; HIV Infections; Humans; Leishmania; Leishmaniasis; Microbial Viability; Nelfinavir; Oligopeptides; Saquinavir; Tetrazolium Salts; Thiazoles | 2013 |
Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance.
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Patient Compliance; Viral Load | 2002 |
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor ab
Topics: Carbamates; Cell Line; Coculture Techniques; Drug Resistance, Viral; Furans; Gene Products, gag; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nelfinavir; Protein Precursors; Sulfonamides; Virus Replication | 2002 |
Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Nelfinavir; Retrospective Studies; RNA, Viral; Time Factors; Treatment Refusal; Viral Load; Viremia | 2002 |
Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report.
Topics: Adult; Female; Graft Rejection; HIV Infections; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Liver Failure; Liver Transplantation; Nelfinavir; Osmolar Concentration; Sirolimus | 2002 |
A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.
Topics: Adolescent; Adult; Algorithms; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mutation; Nelfinavir; Retrospective Studies; RNA, Viral; Treatment Outcome; Viral Load | 2002 |
Pharmacokinetics of saquinavir in children during long term treatment.
Topics: Biological Availability; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Long-Term Care; Male; Nelfinavir; Prospective Studies; Saquinavir; Treatment Outcome | 2002 |
[Antiretroviral therapy with nelfinavir for patient infected, by HIV and secondary diabetes mellitus due to indinavir].
Topics: Adult; Diabetes Mellitus; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir | 2002 |
Supplement fix for nelfinavir-related diarrhea.
Topics: Diarrhea; Dietary Fiber; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Probiotics | 2002 |
Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Nelfinavir; RNA, Viral; Sequence Analysis, RNA; Treatment Failure; Viral Load | 2003 |
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Prospective Studies; Statistics, Nonparametric; Treatment Failure | 2003 |
Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations.
Topics: Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Recurrence; Reverse Transcriptase Inhibitors; Treatment Failure | 2003 |
Chronic cough induced by abacavir apart from a context of hypersensitivity.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chronic Disease; Cough; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Middle Aged; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Rhinitis; Sputum; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination | 2002 |
Estimating the length of the first antiretroviral therapy regiment durability in São Paulo, Brazil.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Cohort Studies; Drug Administration Schedule; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Compliance; Retrospective Studies; Time Factors; Zidovudine | 2002 |
Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Benzoxazines; Bupropion; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Oxazines; Retrospective Studies; Ritonavir; Seizures | 2003 |
SOLO trial results released.
Topics: Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; Humans; Nelfinavir; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides | 2003 |
Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
Topics: Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Drug Interactions; HIV; HIV Infections; Humans; Infant; Male; Mycobacterium tuberculosis; Nelfinavir; Rifampin; Ritonavir; RNA, Viral; Tuberculosis, Pulmonary; Viral Load | 2003 |
[HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].
Topics: Anti-HIV Agents; Codon; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Italy; Male; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy | 2002 |
NEAT results released.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Multicenter Studies as Topic; Nelfinavir; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Resistance data also presented.
Topics: Drug Resistance, Viral; HIV Infections; Humans; Nelfinavir; Ritonavir; Treatment Outcome | 2003 |
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, High Pressure Liquid; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 2003 |
Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
Topics: Antiretroviral Therapy, Highly Active; Child; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir | 2003 |
Nelfinavir potency concerns.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Nelfinavir; Reverse Transcriptase Inhibitors | 2000 |
Prevalence and virologic consequences of HIV-1 genotype mutations detected in a cohort of 161 Italian patients receiving a nelfinavir-based highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Nelfinavir; Prevalence; Treatment Outcome | 2003 |
Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
Topics: Adult; Arteriosclerosis; Biomarkers; Black People; C-Reactive Protein; Calcium; Cholesterol; Coronary Artery Disease; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir | 2003 |
Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.
Topics: Adult; Female; Gestational Age; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydrocortisone; Indinavir; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Viral Load | 2003 |
Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.
Topics: Adult; Aged; Ambulatory Care; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Nelfinavir; Retrospective Studies; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Time Factors; Urban Population | 2003 |
NEAT trial releases results.
Topics: Carbamates; Furans; HIV Infections; Humans; Multicenter Studies as Topic; Nelfinavir; Organophosphates; Prodrugs; Protease Inhibitors; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Viral Load | 2002 |
Nelfinavir tolerated in HCV patients.
Topics: Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Function Tests; Nelfinavir | 2002 |
Characterizing classes of antiretroviral drugs by genotype.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cluster Analysis; Genotype; HIV Infections; HIV-1; Humans; Indinavir; Models, Genetic; Models, Statistical; Molecular Sequence Data; Nelfinavir | 2003 |
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.
Topics: Adolescent; Adult; Africa, Western; Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Codon; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Genes, pol; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sequence Alignment; Sequence Homology, Amino Acid; Sweden; Treatment Failure; Viremia; Zidovudine | 2003 |
Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
Topics: Adolescent; Body Surface Area; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Nelfinavir; Retrospective Studies; RNA, Viral | 2003 |
Summaries for patients. Does marijuana affect viral loads in people with HIV?
Topics: Administration, Oral; Cannabinoids; Dronabinol; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; RNA, Viral; Viral Load | 2003 |
[Use of antiretroviral drugs in HIV infected children in a tropical area: a real benefit].
Topics: Adolescent; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Comorbidity; Cote d'Ivoire; Cyclopropanes; Developing Countries; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Malnutrition; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2003 |
Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV-2; Humans; Indinavir; Male; Middle Aged; Mutation; Nelfinavir; Patient Compliance; Viral Load | 2003 |
Pfizer announces free drug program.
Topics: Anti-Retroviral Agents; Delavirdine; Drug Industry; HIV Infections; Humans; Nelfinavir; United States | 2003 |
Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
Topics: Biotransformation; Cohort Studies; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; RNA, Viral; Time Factors; Treatment Failure; Viral Load | 2003 |
Nelfinavir safe and effective in HIV/HCV patients.
Topics: Clinical Trials as Topic; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 2003 |
Antiretroviral therapy influences cellular susceptibility to apoptosis in vivo.
Topics: Adult; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apoptosis; Drug Combinations; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Zidovudine | 2004 |
[Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Time Factors; Viral Load | 2003 |
Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
Topics: Adult; Alopecia; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Nelfinavir; Pyrimidinones; Ritonavir; Stavudine | 2003 |
Comparison of regimens as initial therapy for HIV.
Topics: Anti-Retroviral Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Treatment Outcome | 2004 |
[Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for "once daily" administration].
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Nelfinavir; Oligopeptides; Oxazines; Pyridines | 2003 |
Mitochondrial effects of antiretroviral therapies in asymptomatic patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Base Sequence; Cross-Sectional Studies; Didanosine; DNA Primers; DNA, Mitochondrial; Female; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Nelfinavir; Nevirapine; Polymerase Chain Reaction; Stavudine | 2004 |
Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors | 2004 |
Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Flow Cytometry; Genes, MDR; HIV Infections; HIV Protease Inhibitors; Humans; Metabolic Clearance Rate; Nelfinavir; Statistics, Nonparametric; Tissue Distribution | 2004 |
Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Felodipine; Female; Follow-Up Studies; HIV Infections; Humans; Needlestick Injuries; Nelfinavir; Risk Assessment; Severity of Illness Index | 2004 |
In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes.
Topics: Antiretroviral Therapy, Highly Active; Excipients; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Reverse Transcriptase Inhibitors; Saquinavir | 2004 |
Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling.
Topics: Adult; Aspartic Acid Endopeptidases; Calcium Signaling; Carbachol; Cell Line; Cell Membrane; Chlorides; Cytosol; Diarrhea; Drug Synergism; Electric Conductivity; HIV Infections; HIV-1; Humans; Intestinal Mucosa; Intracellular Membranes; Middle Aged; Muscarinic Agonists; Nelfinavir; Protease Inhibitors; Time Factors | 2004 |
Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Nevirapine; Stavudine; Viral Load | 2004 |
Protease inhibitor therapy improves protein catabolism in prepubertal children with HIV infection.
Topics: Body Composition; Body Weight; Carbon Isotopes; CD4 Lymphocyte Count; Child; Child, Preschool; Clinical Trials as Topic; Drug Administration Schedule; Energy Metabolism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infusions, Intravenous; Leucine; Male; Muscle Proteins; Nelfinavir; Time Factors; Viral Load | 2004 |
Lamivudine 300 mg in HIV infection: dose change. Once-a-day dosing.
Topics: Adult; Child; Drug Therapy, Combination; France; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Protease Inhibitors; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2004 |
Risk of birth defects associated with nelfinavir exposure during pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-HIV Agents; Birth Weight; Cohort Studies; Female; Gestational Age; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Prospective Studies; Registries; Risk | 2004 |
Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.
Topics: Adult; Anti-Retroviral Agents; Antidiarrheals; Antiretroviral Therapy, Highly Active; Cohort Studies; Diarrhea; Georgia; HIV Infections; Humans; Incidence; Lopinavir; Middle Aged; Nelfinavir; Pyrimidinones; Retrospective Studies; Ritonavir; United States; United States Department of Veterans Affairs | 2004 |
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
Topics: Antiretroviral Therapy, Highly Active; Chi-Square Distribution; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Retrospective Studies; Treatment Outcome; Viral Load | 2004 |
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Nelfinavir; Nevirapine; Oxazines; Prospective Studies; Viral Load | 2004 |
Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.
Topics: Cell Line; Cloning, Molecular; DNA Primers; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Isoenzymes; Mutation; Nelfinavir; Phenotype; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Transfection; Virus Replication | 2004 |
Sweet's syndrome following abacavir therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Sweet Syndrome; Trimethoprim, Sulfamethoxazole Drug Combination | 2004 |
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.
Topics: Child; Child, Preschool; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir | 2004 |
Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
Topics: Adult; Amniotic Fluid; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Maternal-Fetal Exchange; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Sulfonamides | 2004 |
Nelfinavir plasma concentrations are low during pregnancy.
Topics: Adult; Confounding Factors, Epidemiologic; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Pregnancy Trimester, Second; Pregnancy Trimester, Third | 2004 |
[HAART and pregnancy. Nelfinavir superiority in hepatotoxicity].
Topics: Abnormalities, Drug-Induced; Animals; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Risk Assessment | 2004 |
Therapeutic drug monitoring of nelfinavir in pregnancy: a case report.
Topics: Adult; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Viral Load | 2004 |
Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Oligopeptides; Organophosphonates; Oxazines; Pregnancy; Pyrimidinones; Ritonavir; Stavudine; Sulfonamides; Treatment Outcome; Viral Load; Zidovudine | 2004 |
Alternative, age- and viral load-related routes of nelfinavir resistance in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
Topics: Age Factors; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Nelfinavir; Pharmacogenetics; Risk Factors; Sampling Studies; Sensitivity and Specificity; Viral Load | 2004 |
[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Fetus; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nelfinavir; Netherlands; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Treatment Outcome; Viral Load | 2004 |
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Liver; Lopinavir; Male; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Saquinavir; Treatment Outcome | 2004 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2005 |
Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cross-Over Studies; Cyclophosphamide; Doxorubicin; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nelfinavir; Prednisone; Prospective Studies; Vincristine | 2005 |
An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Cytochrome P-450 Enzyme System; Female; Genes, MDR; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Polymorphism, Single Nucleotide; RNA, Viral; Treatment Outcome | 2005 |
Postexposure prophylaxis after sexual assaults: a prospective cohort study.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Brazil; Child; Child, Preschool; Cohort Studies; Drug Administration Schedule; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Compliance; Prospective Studies; Rape; Sexually Transmitted Diseases; Zidovudine | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
Topics: Carbamates; Chronic Disease; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Nelfinavir; Retrospective Studies; Sulfonamides; Virus Replication; Withholding Treatment | 2005 |
Nelfinavir and nevirapine side effects during pregnancy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperglycemia; Nausea; Nelfinavir; Netherlands; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2005 |
The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; HIV Infections; Humans; Lamivudine; Male; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Assessment; Risk-Taking; Stavudine; Tenofovir; Zidovudine | 2005 |
Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels, and anthropometric parameters of their neonates.
Topics: Adolescent; Adult; Anti-HIV Agents; Birth Weight; Case-Control Studies; CD4 Lymphocyte Count; Female; Fetal Development; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; RNA, Viral; Zidovudine | 2005 |
Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Nelfinavir; RNA, Viral; Sweden; Treatment Failure; Viral Load | 2005 |
Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Brazil; Cervix Uteri; Cross-Sectional Studies; Cyclopropanes; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Nelfinavir; Prevalence; Time Factors; Vagina; Viral Load; Zidovudine | 2006 |
TDM: therapeutic drug measuring or therapeutic drug monitoring?
Topics: Anti-Retroviral Agents; Carbamazepine; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; HIV Infections; Humans; Indinavir; Nelfinavir; Nevirapine; Patient Compliance; Quality Control; Surveys and Questionnaires | 2005 |
Limited sampling strategy for the estimation of systemic exposure to the protease inhibitor nelfinavir.
Topics: Area Under Curve; Blood Specimen Collection; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 2005 |
Abnormalities in plasma fatty acid composition in human immunodeficiency virus-infected children treated with protease inhibitors.
Topics: Child; Cholesterol; Cross-Sectional Studies; Fatty Acids; Fatty Acids, Unsaturated; Female; HIV Infections; HIV Protease Inhibitors; Humans; Insulin-Like Growth Factor I; Male; Nelfinavir; Ritonavir; Triglycerides | 2005 |
Nelfinavir in HIV-HCV coinfected patients: a 24-month follow-up in a cohort of 82 patients.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Male; Nelfinavir; Reverse Transcriptase Inhibitors; Viral Load | 2005 |
HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment.
Topics: Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nelfinavir; Treatment Failure | 2005 |
Safety of nelfinavir use during pregnancy. An experimental approach in rats.
Topics: Animals; Female; HIV Infections; HIV Protease Inhibitors; Kidney; Liver; Male; Nelfinavir; Pregnancy; Pregnancy Outcome; Random Allocation; Rats; Rats, Wistar; Specific Pathogen-Free Organisms | 2005 |
Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine; Treatment Failure | 2006 |
Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.
Topics: Drug Resistance, Multiple, Viral; Evolution, Molecular; Gene Products, gag; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Treatment Failure | 2006 |
Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Immunoglobulin G; Male; Middle Aged; Nelfinavir; Neopterin; RNA, Viral; Saquinavir | 2006 |
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
Topics: Carbamates; Codon; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Nelfinavir; Phenotype; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.
Topics: Anti-HIV Agents; Cerebrospinal Fluid; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance.
Topics: Adult; Anti-HIV Agents; Female; Hepatitis C; HIV Infections; Humans; Male; Methadone; Middle Aged; Nelfinavir; Opioid-Related Disorders; Retrospective Studies | 2006 |
Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Male; Nelfinavir; Retrospective Studies; Risk Factors | 2006 |
Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Topics: Amino Acid Substitution; CD4 Lymphocyte Count; Drug Resistance, Viral; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nelfinavir; Phylogeny; Polymorphism, Genetic; Prevalence; RNA, Viral; Selection, Genetic; Treatment Failure; Viral Load; Virus Replication | 2006 |
Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Nelfinavir; Netherlands; Risk Assessment; Severity of Illness Index; Tetrahydronaphthalenes; Treatment Outcome; Viral Load | 2006 |
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases.
Topics: Adult; Antifungal Agents; Drug Synergism; Drug Therapy, Combination; Fluconazole; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Ritonavir | 2006 |
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breath Tests; Cohort Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Female; HIV Infections; Humans; Indinavir; Liver; Male; Nelfinavir; Nevirapine; Ritonavir; Sex Factors | 2006 |
Instrumental variables and interactions in the causal analysis of a complex clinical trial.
Topics: Anti-HIV Agents; Child; Data Interpretation, Statistical; Female; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Models, Statistical; Nelfinavir; Patient Compliance; Randomized Controlled Trials as Topic; RNA, Viral | 2007 |
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
Topics: Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third | 2006 |
Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; British Columbia; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Nelfinavir; Patient Compliance; Pyrimidinones; Ritonavir; Saquinavir; Viral Load | 2006 |
Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.
Topics: Algorithms; Bayes Theorem; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Models, Genetic; Nelfinavir; Phenotype; Polymorphism, Genetic; Pyridines; Pyrones; Ritonavir; Sulfonamides | 2006 |
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Genetic Variation; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Orosomucoid; Oxazines; Phenotype; Pyrimidinones; Ritonavir; Switzerland | 2006 |
CD4 count and viral load time-courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Centers for Disease Control and Prevention, U.S.; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Prospective Studies; Spain; United States; Viral Load | 2006 |
Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cohort Studies; Cote d'Ivoire; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.
Topics: Bayes Theorem; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Saquinavir | 2007 |
Detection of HIV protease inhibitors in alveolar epithelial lining fluid: relevance for modulation of pneumocystis infection in the course of HAART.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Active; Bronchoalveolar Lavage Fluid; Bronchoscopy; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Pneumocystis carinii; Pneumocystis Infections; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients.
Topics: Aged; Alkynes; Benzoxazines; Case-Control Studies; Cyclopropanes; Electrocardiography; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Risk Factors; Zidovudine | 2007 |
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
Topics: Base Sequence; California; Drug Resistance, Multiple, Viral; Evolution, Molecular; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Molecular Sequence Data; Nelfinavir | 2006 |
Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Ritonavir; Saquinavir | 2007 |
HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.
Topics: Alkaline Phosphatase; Calcium; Cell Line; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oligonucleotide Array Sequence Analysis; Osteoblasts; Ritonavir; Saquinavir; Tissue Inhibitor of Metalloproteinase-3; Up-Regulation | 2007 |
Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Prognosis; Prospective Studies; Sex Characteristics; Treatment Outcome; Viral Load | 2007 |
Paronychia in an HIV-infected patient under nelfinavir therapy.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Paronychia | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Factors associated with poor immunologic responses despite viral suppression in markedly immunosuppressed patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; Humans; Immunocompromised Host; Male; Nelfinavir; Reverse Transcriptase Inhibitors; Risk Factors; Viral Load | 2007 |
Uncomplicated outcome after an accidental overdose of nevirapine in a newborn.
Topics: Anti-HIV Agents; Drug Overdose; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Medication Errors; Nelfinavir; Nevirapine | 2008 |
Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification.
Topics: Amino Acid Substitution; Drug Resistance, Viral; HIV; HIV Infections; Humans; Mutation; Nelfinavir; Polymerase Chain Reaction; Sensitivity and Specificity | 2007 |
Antiretroviral agents and acid-base balance at delivery of the neonate.
Topics: Acid-Base Equilibrium; Adult; Anti-HIV Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fetal Blood; HIV Infections; Humans; Hydrogen-Ion Concentration; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nelfinavir; Pregnancy; Pregnancy Outcome; Prospective Studies; Zidovudine | 2007 |
Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Cohort Studies; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Retrospective Studies; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2007 |
Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in HIV-exposed, uninfected newborn infants.
Topics: Adolescent; Adult; Amylases; Anti-HIV Agents; Cohort Studies; Control Groups; Drug Therapy, Combination; Female; Fetal Blood; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Liver; Male; Nelfinavir; Pregnancy; Prospective Studies; Transaminases; Zidovudine | 2007 |
Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
Topics: Alopecia; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Treatment Outcome | 2007 |
Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Reagent Kits, Diagnostic; Sensitivity and Specificity | 2007 |
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Topics: Amino Acid Substitution; Databases, Protein; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Models, Molecular; Mutation; Nelfinavir; Pyrimidinones; Ritonavir; Spain; Treatment Failure | 2007 |
High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004.
Topics: Adolescent; Adult; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Prevalence; Reverse Transcriptase Inhibitors; United States | 2007 |
Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.
Topics: Amniotic Fluid; Dose-Response Relationship, Drug; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Placenta; Pregnancy; Pregnancy Complications, Infectious; Treatment Outcome | 2007 |
Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
Topics: Adolescent; Age Factors; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Mass Index; Body Weight; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; DNA, Mitochondrial; DNA, Viral; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Lipids; Longitudinal Studies; Mitochondria; Nelfinavir; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral | 2007 |
Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Biotransformation; Body Weight; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Polymorphism, Genetic; Treatment Outcome; Viral Load | 2008 |
HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
Topics: Adult; Algorithms; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Viral Load | 2007 |
Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zidovudine | 2007 |
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Topics: Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Longitudinal Studies; Lopinavir; Male; Nelfinavir; Pregnancy; Pyrimidinones; Ritonavir; Switzerland; Treatment Outcome; Viral Load; Withholding Treatment | 2008 |
An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma.
Topics: Anti-HIV Agents; Base Sequence; DNA Probes; Evaluation Studies as Topic; Genetic Variation; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Molecular Probe Techniques; Molecular Sequence Data; Nelfinavir; Nucleic Acid Amplification Techniques; Reproducibility of Results; RNA, Viral; Sensitivity and Specificity; Sulfonic Acids; Virology | 1996 |
More new drugs for HIV and associated infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytomegalovirus Retinitis; Cytosine; HIV Infections; Humans; Isoquinolines; Nelfinavir; Nevirapine; Organophosphonates; Organophosphorus Compounds; Protease Inhibitors; Pyridines; Ritonavir; Sulfonic Acids | 1997 |
FDA rapidly approves HIV protease inhibitors for children.
Topics: Adult; Anti-HIV Agents; Child; Drug Industry; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Ritonavir; Sulfonic Acids; United States; United States Food and Drug Administration | 1997 |
Decay characteristics of HIV-1-infected compartments during combination therapy.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Lamivudine; Leukocytes, Mononuclear; Macrophages; Mathematics; Models, Biological; Nelfinavir; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonic Acids; Viral Load; Viremia; Virus Latency; Zidovudine | 1997 |
FDA approvals include two new AIDS drugs, pediatric labeling for two protease inhibitors.
Topics: Adolescent; Adult; Child; Child, Preschool; Delavirdine; Drug Approval; Drug Labeling; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Isoquinolines; Nelfinavir; Piperazines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonic Acids; United States; United States Food and Drug Administration | 1997 |
Anti-HIV effects of Viracept persist during long periods of combination therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Safety; Sulfonic Acids | 1997 |
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.
Topics: Adenosine; Anti-HIV Agents; Cytidine; DNA; DNA, Viral; Drug Therapy, Combination; Guanosine; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Nelfinavir; Nucleic Acid Hybridization; RNA, Viral; Sulfonic Acids; Zidovudine | 1997 |
Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
Topics: Cell Survival; Cells, Cultured; Drug Combinations; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Nelfinavir; Protease Inhibitors; Reverse Transcriptase Inhibitors | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Saquinavir | 1997 |
Confusion of nelfinavir and nevirapine.
Topics: Anti-HIV Agents; Drug Labeling; Female; HIV Infections; Humans; Medication Errors; Nelfinavir; Nevirapine; Pharmacy | 1998 |
Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Patient Education as Topic; Primary Nursing; Ritonavir; Saquinavir | 1998 |
[Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Topics: Diabetes Complications; Diabetes Mellitus; HIV Infections; HIV Protease Inhibitors; Humans; Hyperglycemia; Indinavir; Nelfinavir; Ritonavir; Saquinavir | 1997 |
Exacerbated hyperglycemia associated with nelfinavir.
Topics: Diabetes Complications; Diabetes Mellitus; HIV Infections; HIV Protease Inhibitors; Humans; Hyperglycemia; Male; Middle Aged; Nelfinavir | 1998 |
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Topics: Adult; Anti-HIV Agents; Body Composition; Cross-Sectional Studies; Diabetes Mellitus; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Insulin Resistance; Lipodystrophy; Male; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Syndrome | 1998 |
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors | 1998 |
A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity.
Topics: Anti-HIV Agents; CD4-CD8 Ratio; Dose-Response Relationship, Drug; Drug Resistance, Microbial; HIV; HIV Infections; Humans; Models, Theoretical; Nelfinavir; Zidovudine | 1997 |
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
Topics: Amino Acid Substitution; Carbamates; Clinical Trials as Topic; Databases, Factual; DNA, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Methionine; Nelfinavir; Phenotype; Polymerase Chain Reaction; Ritonavir; Saquinavir; Sulfonamides; Valine | 1998 |
Nelfinavir-induced urticaria and successful desensitization.
Topics: Adult; CD4-Positive T-Lymphocytes; Desensitization, Immunologic; Drug Hypersensitivity; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Urticaria | 1998 |
HIV-1 peripheral neuropathy and combination antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nelfinavir; Nevirapine; Peripheral Nervous System Diseases; Saquinavir; Zidovudine | 1998 |
Report updates recommendations for health workers exposed to HIV.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Occupational Exposure; Practice Guidelines as Topic; United States; United States Public Health Service; Zidovudine | 1998 |
[Observance, adherence, compliance ...different words for better therapeutic results].
Topics: Anti-HIV Agents; Antiviral Agents; HIV Infections; Humans; Nelfinavir; Patient Compliance; Retroviridae Infections | 1998 |
[The role of nelfinavir in the triple-therapy of HIV infection].
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Male; Nelfinavir | 1999 |
Liposuction for protease-inhibitor-associated lipodystrophy.
Topics: HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipectomy; Lipodystrophy; Male; Middle Aged; Nelfinavir; Saquinavir | 1999 |
A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin.
Topics: Adult; Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Phenytoin; Recurrence; Seizures | 1999 |
High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver Diseases; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Stavudine | 1999 |
Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reproducibility of Results; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet | 1999 |
Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Genetic Variation; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Dynamic correlation of apoptosis and immune activation during treatment of HIV infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Apoptosis; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Drug Therapy, Combination; fas Receptor; HIV Infections; HIV Protease Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Nelfinavir; Nucleosides; Reverse Transcriptase Inhibitors; Saquinavir; T-Lymphocytes | 1999 |
Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Retrospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Treatment Failure; Viral Load | 1999 |
Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; Prognosis; Retrospective Studies; Ritonavir | 1999 |
Abacavir rechallenge has to be avoided in case of hypersensitivity reaction.
Topics: Anaphylaxis; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Fatal Outcome; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors | 1999 |
Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge.
Topics: Adult; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Pancreatitis; Reverse Transcriptase Inhibitors | 1999 |
Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Topics: Adult; Anti-HIV Agents; Arteriosclerosis; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Indinavir; Lipids; Lipoprotein(a); Lipoproteins; Logistic Models; Male; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Thyrotropin | 1999 |
Symptomatic junctional bradycardia after treatment with nelfinavir.
Topics: Bradycardia; Electrocardiography; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nelfinavir | 1999 |
Effect of protease inhibitors on the sense of taste.
Topics: Adult; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Taste; Taste Disorders | 1999 |
Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Renal Insufficiency; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Activity of the combination of nelfinavir and saquinavir against human immunodeficiency virus after failure of prior protease inhibitor therapy.
Topics: Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Retrospective Studies; Salvage Therapy; Saquinavir; Treatment Failure; Treatment Outcome | 1999 |
Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual.
Topics: Administration, Oral; Anti-HIV Agents; Drug Therapy, Combination; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Nevirapine; Peptides; Reverse Transcriptase Inhibitors; Saquinavir | 1999 |
Two possible pathways for acquisition of mutations related to nelfinavir resistance.
Topics: Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Nelfinavir; Ritonavir; Saquinavir | 1999 |
Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Basal Metabolism; Body Composition; Body Weight; Case-Control Studies; Cohort Studies; Didanosine; Energy Metabolism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Longitudinal Studies; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Viremia | 1999 |
Choosing the best initial therapy for HIV-1 infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral | 1999 |
Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases.
Topics: Adult; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Risk Factors; Ritonavir; Saquinavir; Venous Thrombosis | 1999 |
Remission of HIV myelopathy after highly active antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Nelfinavir; Remission Induction; Spinal Cord Diseases; Stavudine | 2000 |
Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
Topics: Adolescent; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Prognosis; Retrospective Studies; Ritonavir; Salvage Therapy; Saquinavir; Treatment Outcome | 2000 |
Virologic response associated with a change in protease inhibitor therapy.
Topics: HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; RNA, Viral; Treatment Outcome | 2000 |
Four-drug salvage antiretroviral treatment including nelfinavir and efavirenz in highly treated children with congenital HIV disease.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Male; Nelfinavir; Oxazines; Salvage Therapy | 2000 |
Decrease in methodone levels with nelfinavir mesylate.
Topics: Adult; Comorbidity; HIV Infections; HIV Protease Inhibitors; Humans; Male; Methadone; Nelfinavir; Opioid-Related Disorders | 2000 |
Are nelfinavir-containing regimens effective as second-line triple therapy?
Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Nelfinavir; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine | 2000 |
Pharmacokinetics of nelfinavir during haemodialysis in a patient with HIV infection.
Topics: Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Renal Dialysis; Renal Insufficiency | 2000 |
Rash as side-effect of nelfinavir in children.
Topics: Adrenal Cortex Hormones; Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Erythema; Female; Histamine H1 Antagonists; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Nelfinavir; Reverse Transcriptase Inhibitors | 2000 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Furans; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymph Nodes; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Sulfonamides; Time Factors; Viral Load; Viremia; Zidovudine | 2000 |
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Outcome; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome; Zidovudine | 2000 |
Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Zidovudine | 2000 |
Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.
Topics: Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Didanosine; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Jurkat Cells; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; T-Lymphocytes; Viral Load; Zidovudine | 2000 |
Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Kidney Failure, Chronic; Nelfinavir; Nevirapine; Peritoneal Dialysis, Continuous Ambulatory; Reverse Transcriptase Inhibitors | 2000 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
Topics: Alkynes; Benzoxazines; Calibration; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Lipodystrophy: results of a data evaluation of patients receiving nelfinavir-containing combination therapy.
Topics: Anti-HIV Agents; Databases, Factual; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Lipodystrophy; Nelfinavir; Retrospective Studies; Reverse Transcriptase Inhibitors | 2000 |
Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV).
Topics: Drug Interactions; Drug Monitoring; Hemophilia A; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nelfinavir; Tacrolimus | 2000 |
Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lipodystrophy; Nelfinavir; Prospective Studies | 2000 |
Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis.
Topics: Adolescent; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Transfusion Reaction; Zidovudine | 2000 |
[Holding option open for subsequent treatment. Beginning therapy with a protease inhibitor].
Topics: Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Viral Load | 2000 |
Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child.
Topics: Anti-HIV Agents; Antibody Formation; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Antibodies; HIV Infections; HIV Seronegativity; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Viremia; Zidovudine | 2000 |
Medication bezoar and esophagitis in a patient with HIV infection receiving combination antiretroviral therapy.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Bezoars; Esophagitis; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Patient Education as Topic | 2000 |
Hyperlipidemia associated with the use of protease inhibitors.
Topics: Adult; Anti-HIV Agents; Cholesterol; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Triglycerides | 2000 |
Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Zidovudine | 2000 |
Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors | 2000 |
HIV-1 resistance genotyping by sequencing produces inconsistent results for mixed viral populations.
Topics: Anti-HIV Agents; Base Sequence; Codon; DNA, Viral; Drug Resistance, Microbial; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nelfinavir; Point Mutation | 2000 |
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Confidence Intervals; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; HIV Infections; HIV Protease Inhibitors; Humans; Linear Models; Liver Diseases; Male; Mixed Function Oxygenases; Nelfinavir | 2000 |
Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Logistic Models; Male; Nelfinavir; Patient Compliance; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Statistics, Nonparametric; Stavudine; Substance Abuse, Intravenous | 2000 |
Surveillance of antiretroviral prescriptions.
Topics: Anti-HIV Agents; Data Collection; Drug Prescriptions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Puerto Rico; Stavudine; United States | 2000 |
Switching antiretroviral therapy from an enzyme-inducing drug.
Topics: Adult; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Viral Load | 2000 |
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma.
Topics: Adult; Anti-HIV Agents; Central Nervous System; Drug Resistance, Microbial; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Time Factors | 2000 |
Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors | 2000 |
In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.
Topics: Anti-HIV Agents; Chemokine CXCL12; Chemokines, CXC; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Methionine; Nelfinavir; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.
Topics: Adult; Chromatography, High Pressure Liquid; Cohort Studies; DNA, Viral; Female; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; Sequence Analysis, DNA; Viral Load | 2000 |
Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Lymphocytes; Macrophage Inflammatory Proteins; Male; Nelfinavir; Stavudine; Viral Load; Viremia | 2000 |
No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients.
Topics: Antimalarials; Antiretroviral Therapy, Highly Active; Drug Interactions; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Malaria; Mefloquine; Nelfinavir | 2000 |
Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Depression, Chemical; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxyurea; Immunity, Cellular; Indinavir; Lamivudine; Lymphocyte Count; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Refusal; Viral Load; Viremia; Zidovudine | 2001 |
Induction-maintenance (5 --> 3 drugs) in HIV-infected patients with high viral load.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; Humans; Lamivudine; Nelfinavir; Nitriles; Prospective Studies; Pyrrolidines; Remission Induction; Saquinavir; Stavudine; Treatment Outcome; Viral Load | 2000 |
Protease inhibitor therapy in HIV-infected children.
Topics: Adolescent; Age Factors; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Male; Nelfinavir; Patient Compliance; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2000 |
Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
Topics: Adult; Aged; Anti-HIV Agents; Drug Resistance, Microbial; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Nelfinavir; Phenotype | 2001 |
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Contact Tracing; Counseling; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Compliance; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Sexually Transmitted Diseases, Viral; Substance Abuse, Intravenous; Time Factors; Zidovudine | 2001 |
ICAAC: nelfinavir interacts with statins and an antiseizure drug.
Topics: Anticholesteremic Agents; Anticonvulsants; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nelfinavir; Phenytoin; Pyrroles; Simvastatin | 2000 |
Lack of removal of nelfinavir during a haemodialysis session in an HIV-1 infected patient with hepatic and renal insufficiency.
Topics: Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver Failure; Middle Aged; Nelfinavir; Renal Dialysis; Renal Insufficiency | 2001 |
The safety and antiviral effect of protease inhibitors in children.
Topics: Adolescent; Blood Chemical Analysis; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Male; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Viral Load | 2001 |
Failure of postexposure prophylaxis after sexual exposure to HIV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Copulation; Female; HIV Antibodies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Treatment Failure; Viral Load; Zidovudine | 2001 |
Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Nelfinavir; Retrospective Studies; RNA, Viral | 2001 |
Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
Topics: Adult; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Resistance, Microbial; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Phenotype; RNA, Viral; Treatment Failure; Viral Load | 2001 |
Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Indinavir; Lamivudine; Nelfinavir; Occupational Exposure; Reverse Transcriptase Inhibitors; Thyroxine; Zidovudine | 2001 |
Nelfinavir desensitization.
Topics: Adult; Desensitization, Immunologic; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Treatment Outcome; Viral Load | 2001 |
Ergotism related to interaction between nelfinavir and ergotamine.
Topics: Adult; Drug Interactions; Ergotamine; Ergotism; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Vasoconstrictor Agents | 2001 |
Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.
Topics: Adult; Amino Acid Sequence; Catalysis; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Nelfinavir; Protein Structure, Secondary; Ritonavir; Saquinavir; Uganda | 2001 |
Anti-HIV effects of nelfinavir reported after ten months of combination therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphoid Tissue; Nelfinavir; Zidovudine | 1997 |
Data on nevirapine combinations released.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Nevirapine; Viral Load | 1998 |
Agouron protease inhibitor AG1343: activity reported.
Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 1995 |
Clinical potential of a new HIV protease inhibitor.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; HIV-1; Male; Nelfinavir; RNA, Viral | 1995 |
Protease inhibitor trials moving to next phase.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication | 1995 |
The next wave of protease inhibitors.
Topics: Animals; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 1995 |
Agouron protease inhibitor.
Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 1995 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
Closing the circle on HIV--or not.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Nelfinavir; Prognosis; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Protease inhibitors at Retroviruses Conference: Agouron's results.
Topics: Antiviral Agents; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Nelfinavir; Stavudine | 1996 |
Anti-HIV agents at ICAAC.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Kidney; Mutation; Nelfinavir; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonic Acids; Treatment Failure; Viral Load | 1996 |
Pediatric treatments.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Ritonavir; Sulfonic Acids; United States; United States Food and Drug Administration | 1997 |
Large trial started for Viracept.
Topics: Child; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Reverse Transcriptase Inhibitors; Sulfonic Acids; United States | 1997 |
Nelfinavir at six months.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Sulfonic Acids; Viral Load; Zidovudine | 1997 |
Fourth protease inhibitor hits the market.
Topics: Drug Approval; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Sulfonic Acids; United States; United States Food and Drug Administration | 1997 |
Nelfinavir - major trial results at retroviruses conference.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Stavudine; Sulfonic Acids; Viral Load; Zidovudine | 1997 |
Nelfinavir (Viracept) approved: fourth protease inhibitor available.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Approval; Drug Costs; Drug Therapy, Combination; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Sulfonic Acids; United States; United States Food and Drug Administration | 1997 |
Nelfinavir combination therapy: ten-month report.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Sulfonic Acids; United States; Viral Load | 1997 |
FDA approves nelfinavir. Food and Drug Administration.
Topics: Adult; Child; Drug Approval; Drug Costs; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Sulfonic Acids; United States; United States Food and Drug Administration | 1997 |
New drug approved to treat HIV.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Diarrhea; Drug Approval; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Sulfonic Acids; United States; United States Food and Drug Administration; Viral Load | 1997 |
Newly approved PI provides treatment options.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Sulfonic Acids; Viral Load; Zidovudine | 1997 |
Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonic Acids | 1997 |
Nelfinavir: fourth protease inhibitor approved.
Topics: Adult; Child; Drug Approval; Drug Interactions; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Nelfinavir; Sulfonic Acids; United States; United States Food and Drug Administration | 1997 |
Nelfinavir (Viracept).
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; Sulfonic Acids; United States; United States Food and Drug Administration; Viral Load; Virus Replication; Zidovudine | 1997 |
New developments in women and AIDS research.
Topics: AIDS-Related Opportunistic Infections; Delavirdine; Drug Therapy, Combination; Estrogens; Female; HIV Infections; HIV Protease Inhibitors; HIV Wasting Syndrome; Humans; Indoles; Infant; Infectious Disease Transmission, Vertical; Isoquinolines; Nelfinavir; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Sulfonic Acids; Zidovudine | 1997 |
Simplifying drug regimens.
Topics: Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Drug Administration Schedule; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Patient Compliance; Reverse Transcriptase Inhibitors; Viral Load | 1998 |
Update on antivirals.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dosage Forms; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1997 |
Other options: clinical trials.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Patient Selection; Salvage Therapy; Treatment Failure; Viral Load | 1998 |
Combinations of protease inhibitors.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Viral Load | 1998 |
Indinavir, nelfinavir -- twice a day?
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir | 1998 |
Medical marijuana study in San Francisco: pays $1000, 25 days in hospital.
Topics: Cannabis; Clinical Trials as Topic; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Patient Selection; Phytotherapy; San Francisco | 1998 |
Pregnant pause.
Topics: Anti-HIV Agents; Contraceptives, Oral; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir | 1998 |
Salvage with Nelfinavir doesn't always work.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Salvage Therapy; Viral Load | 1998 |
Antiviral update.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Menstrual Cycle; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Viral Load | 1998 |
Nelfinavir access in Canada.
Topics: Anti-HIV Agents; Canada; Drug Costs; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 1998 |
Antivirals and children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Nelfinavir; Practice Guidelines as Topic; Ritonavir; Saquinavir; Viral Load | 1998 |
Salvage therapy studies.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy; Saquinavir; Viral Load | 1998 |
Too little of a good thing.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Nelfinavir; Patient Compliance; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Stavudine; Viral Load | 1998 |
Nelfinavir (Viracept) price increase 4.6 percent.
Topics: Drug Costs; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 1998 |
Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference.
Topics: Adenine; Antiviral Agents; Bacterial Vaccines; Carbamates; Congresses as Topic; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Pneumococcal Infections; Sulfonamides; Vaccination; Viral Load | 1998 |
Ultrase and Viracept.
Topics: Clinical Trials as Topic; Diarrhea; Drug Interactions; Enzyme Therapy; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; New York City; Pancreas; Washington | 1999 |
Viracept and irregular heartbeat warning.
Topics: Adult; Anti-HIV Agents; Bradycardia; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir | 1999 |
Twice-daily dosing of Nelfinavir approved.
Topics: Diarrhea; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir | 1999 |
New dosing of ddI (Videx) and Nelfinavir (Viracept) approved.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Pancreatitis; United States Food and Drug Administration | 1999 |
Any toxic relief in sight? The induction/maintenance approach to therapy.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Saquinavir; Stavudine; T-Lymphocytes; Viral Load; Virus Replication | 1998 |
Lack of association between pregnancy and selected gastrointestinal adverse events among women prescribed nelfinavir.
Topics: Adolescent; Adult; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; Humans; Middle Aged; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious | 2001 |
Editorial comment on Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Enzyme Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Mixed Function Oxygenases; Nelfinavir; Omeprazole | 2001 |
Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Genotype; HIV; HIV Infections; Humans; Male; Nelfinavir; RNA, Viral; Salvage Therapy | 2001 |
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reference Standards; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides | 2001 |
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Follow-Up Studies; HIV Infections; Humans; Indinavir; Longitudinal Studies; Middle Aged; Nelfinavir; Prevalence; Protease Inhibitors; Ritonavir; Saquinavir; Viral Load | 2001 |
The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Topics: Adipose Tissue; Adult; Aged; Cholesterol; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Male; Middle Aged; Nelfinavir; Retrospective Studies; Ritonavir; Saquinavir; Triglycerides | 2001 |
Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir.
Topics: Body Mass Index; Bone Density; Cohort Studies; Cross-Sectional Studies; Heart; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Longitudinal Studies; Male; Nelfinavir; Osteocalcin | 2001 |
Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.
Topics: Administration, Oral; Adolescent; Antiretroviral Therapy, Highly Active; Capsules; Child; Child, Preschool; Female; Gelatin; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Prognosis; Reverse Transcriptase Inhibitors; Saquinavir | 2001 |
HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Topics: Adult; Antigens, CD34; Antiretroviral Therapy, Highly Active; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fluorescent Dyes; Hematopoietic Stem Cells; HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Indinavir; Lymphocytes; Male; Nelfinavir; Rhodamine 123; Ritonavir; RNA, Viral; Saquinavir | 2001 |
Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.
Topics: Adult; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir | 2001 |
Lipid abnormalities in a healthcare worker receiving HIV prophylaxis.
Topics: Adult; Allied Health Personnel; Anti-HIV Agents; Cholesterol; Cholesterol, LDL; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Lamivudine; Needlestick Injuries; Nelfinavir; Practice Guidelines as Topic; Renal Dialysis; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Antiretroviral therapy for previously treated patients.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure | 2001 |
Nelfinavir in expanded postexposure prophylaxis causing acute hepatitis with cholestatic features: two case reports.
Topics: Adult; Chemical and Drug Induced Liver Injury; Chemoprevention; Cholestasis; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir | 2001 |
Antiretroviral rounds. When success is a pain.
Topics: Abdominal Pain; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2001 |
Kaletra versus nelfinavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nelfinavir; Pyrimidinones; Ritonavir; Viral Load | 2001 |
Protease inhibitors and blood sugar problems.
Topics: Anti-HIV Agents; Blood Glucose; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Nelfinavir | 2001 |
An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Brain; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Motor Neuron Disease; Nelfinavir; Neurologic Examination; Treatment Outcome; Zidovudine | 2001 |
Long-term response for nelfinavir.
Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Retrospective Studies | 2001 |
Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Nelfinavir; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral | 2001 |
Nelfinavir (Viracept).
Topics: Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Practice Guidelines as Topic | 2000 |
Drugs for HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zidovudine | 2001 |
Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Treatment Failure; Viremia | 2002 |
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Topics: Alkynes; Alleles; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; Genes, MDR; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Nelfinavir; Oxazines; Pharmacogenetics; Polymerase Chain Reaction; Prospective Studies; Treatment Outcome | 2002 |
FDA approves new versions of two HIV/AIDS drugs.
Topics: Delavirdine; Drug Administration Schedule; Drug Approval; HIV Infections; Humans; Nelfinavir; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2000 |
Effect of antiretroviral combination therapies including efavirenz in heavily pretreated HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viremia | 2002 |
Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Anticoagulants; Drug Therapy, Combination; Echocardiography; Follow-Up Studies; HIV Infections; Humans; Hypertension, Pulmonary; Lamivudine; Male; Nelfinavir; Severity of Illness Index; Stavudine; Treatment Outcome; Zidovudine | 2001 |
Metabolic response to a C-glucose load in human immunodeficiency virus patients before and after antiprotease therapy.
Topics: Adult; Blood Glucose; C-Peptide; Calorimetry, Indirect; Carbon Isotopes; Fats; Fatty Acids, Nonesterified; Glucose; Glycogen; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin; Longitudinal Studies; Male; Nelfinavir; Oxidation-Reduction; Time Factors; Urea | 2002 |
Prescribing practices in a population-based HIV postexposure prophylaxis program.
Topics: Accidents; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bites, Human; British Columbia; Community-Acquired Infections; Disease Transmission, Infectious; Drug Prescriptions; Drug Utilization; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mucous Membrane; Needlestick Injuries; Nelfinavir; Occupational Exposure; Practice Patterns, Physicians'; Rape; Reverse Transcriptase Inhibitors; Risk; Skin; Stavudine | 2002 |
Severe HIV-associated thrombocytopenia despite effective highly active antiretroviral therapy in a vertically infected child.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine; Thrombocytopenia | 2002 |
Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.
Topics: Anti-HIV Agents; Chemoprevention; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Nelfinavir; Occupational Exposure; Reverse Transcriptase Inhibitors; Stavudine; Surveys and Questionnaires | 2002 |
[Drug combination therapy for children infected with HIV/AIDS--own experience].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Male; Nelfinavir; Poland; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2001 |
Needlestick transmission of hepatitis C.
Topics: Accidents, Occupational; Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Asthenia; Exanthema; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon alpha-2; Interferon-alpha; Internship and Residency; Lamivudine; Needlestick Injuries; Nelfinavir; Occupational Exposure; Physicians; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia; Zidovudine | 2002 |
Delayed recovery of effector memory CD4+ T cells by highly active antiretroviral therapy in a patient with HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Immunologic Memory; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Time Factors; Zidovudine | 2002 |
Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Nelfinavir; Retrospective Studies; RNA, Viral; Time Factors | 2002 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Adhesive capsulitis of the shoulder in an HIV patient treated with nelfinavir.
Topics: Bursitis; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Shoulder Joint | 2002 |
Male sexual dysfunction associated with antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Cohort Studies; Erectile Dysfunction; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Managed Care Programs; Middle Aged; Nelfinavir; New England; Retrospective Studies; Ritonavir; Saquinavir | 2002 |
Increasing choices for HIV therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2002 |